



13th Conference of the International Society of Travel Medicine

Maastricht, The Netherlands

Maastricht Exhibition and
Conference Centre (MECC)

19-23 May 2013



CISTM13 Program Book



Sanofi Pasteur MSD

the only company
dedicated exclusively
to vaccines

Sanofi Pasteur MSD's commitment

- Develop innovative vaccines for people across Europe.
- Protect all age groups with a highly effective range of vaccines.
- Convey the unique characteristics of vaccines and their value for health.



 www.spmsd.com


sanofi pasteur MSD
vaccines for life

Sanofi Pasteur MSD, 8, rue Jonas Salk 69367 Lyon Cedex 07 - France

Table of Contents

Welcome Letters	3
ISTM President and CISTM13 LOC Chair	3
CISTM13 Scientific Program Committee Chairs.....	5
Organisation	7
CISTM13 Scientific Program Committee	7
CISTM13 Local Organizing Committee	7
CISTM13 Oversight Committee.....	8
ISTM Executive Board	8
Sponsors and Exhibitors	11
Descriptions of Scientific Program Sessions	13
Important Information	15
Admittance Badges	15
Photographs.....	15
Speaker Abstracts.....	15
Wi-Fi Access at the MECC.....	15
Liability	15
Evaluation Form.....	16
Continuing Medical Education (CME) Credits	16
Continuing Education Credits for Nurses.....	16
Accreditation Certificates	16
Faculty Disclosures.....	17
ISTM Charity Donations Program.....	18
Speaker Ready Room	19
Welcome Reception.....	19
Dinner at LaCaverne de Geulhem.....	19
Pre CISTM Courses.....	20
CISTM13 Onsite Registration Information	20



Maps of the Maastricht Exhibition and Conference Centre (MECC)	21
MECC Map Level 0	21
MECC Map Level 1	22
MECC Map Level 2	23
CISTM13 Opening Ceremony	25
CISTM13 Program Schedule	27
Sunday, 19 May 2013	27
Monday, 20 May 2013	28
Tuesday, 21 May 2013.....	39
Wednesday, 22 May 2013.....	51
Thursday, 23 May 2013.....	59
Posters.....	63
Sponsored Satellite Programs	83
GlaxoSmithKline Satellite Symposium Program.....	83
Novartis Vaccines and Diagnostics Satellite Symposium Program	84
ISTM Committee and Group Meetings	85
Related Society Meetings.....	86
Exhibition	87
Exhibition Schedule.....	87
Exhibitor List	88
Exhibition Floor Plan	89
Exhibitor Information	90





Welcome to the CISTM13 at the Maastricht Exhibition and Conference Centre in Maastricht, The Netherlands!



Fiona Genasi

*From the ISTM President and CISTM13
Local Organizing Committee Chair*

**On behalf of the International Society of
Travel Medicine and the Local Organizing
Committee,** we are pleased to welcome



Gerard JB Sonder

you to Maastricht, The Netherlands for the

13th Conference of the International Society of Travel Medicine (CISTM13). We hope you will enjoy visiting Maastricht, a wonderful place to spend time exploring its magnificent buildings, lovely cathedrals and spectacularly cobblestoned town centre. The city is well known for its fine cuisine, excellent shops and multicultural atmosphere. Maastricht is also very compact, and so everything is walking distance, or why not hire a bicycle to get around!

ISTM has now grown to 3,000 members in 90 countries and is the largest organization of professionals dedicated to the advancement of the specialty of travel medicine. Our CISTMs are really outstanding opportunities that occur only every 2 years and allow travel medicine practitioners from around the world to come together to share experiences, enjoy a collegial environment, and do a bit of travelling themselves.

We wish to take this opportunity to thank all of the participating presenters, chairs, Scientific Program Committee and Local Organising Committee members, whose hard work has produced a truly thought-provoking and dynamic programme. These conferences are now established as the leading venue for the practice and science of the discipline of travel medicine, and this is reflected in the outstanding caliber of international experts in the field who will be sharing their knowledge and experience with us over the next few days. From comprehensive review of the basic



foundations of travel medicine, through to original scientific research and new information on disease outbreaks and emerging global health issues, there should be something to benefit all attendees.

We also hope this conference will provide an opportunity for you to become more involved in the ISTM. One way of doing this is for members to attend the ISTM Membership Assembly on Wednesday, 22 May at 17.15, followed by a cocktail reception. During the Assembly you will hear more about the ISTM activities and meet the newly elected ISTM Executive Board. New ISTM members are particularly welcome to attend this session.

Also during the conference, look out for the scheduled membership meetings hosted by each of the ISTM Interest and Professional Groups. Whilst of particular interest to members of these groups, delegates wishing to attend in order to become more actively involved are also very welcome.

ISTM leaders can be identified by ribbons on their delegate badges and will be delighted to answer any questions you have regarding the society and activities of the ISTM. In addition, we encourage you to visit the ISTM booth in the exhibition hall to find out about benefits of membership, society activities, resources, literature and upcoming meetings.

We also wish to thank the sponsors and exhibitors who are participating in the CISTM. Please be sure to take the time to visit their stands in the exhibition. They will be available during the breaks in the scientific program from Monday through Wednesday.

We are certain Maastricht will provide the perfect setting for the kind of friendly and intimate ISTM meeting we all love, and are delighted that you are here to share it with us.

Cheers,

Fiona Genasi, United Kingdom
ISTM President



Gerard JB Sonder, The Netherlands
CISTM13 Local Organizing Committee Chair



Mary E. Wilson

Leo G. Visser

Blaise Genton

Christina Greenaway

From the Chairs of the CISTM13 Scientific Program Committee

Dear Colleagues,

On behalf of the Scientific Program Committee (SPC), we would like to welcome you to the CISTM13 where you will be treated to a stimulating scientific program and can enjoy the many activities and rich history that this wonderful city of Maastricht has to offer. The ISTM has chosen a conveniently located state-of-the-art facility for the conference and has assembled an exciting array of extra-curricular activities. We are fortunate to have confirmed many outstanding and experienced speakers from Europe and around the world who will provide you with the most important and current material in the discipline of travel medicine. The SPC began planning CISTM13 immediately after the meeting wrapped up in Boston. We met for the first time in early 2012 in Maastricht to begin working on the scientific program. We have tried to develop a program that will be exciting and stimulating for all members of our Society with presentations that will cover the latest cutting-edge information in travel medicine as well as topics and clinical challenges that travel medicine practitioners encounter in day-to-day practice.

To develop this program we have carefully considered the feedback from ISTM members from the past CISTM meetings and the suggestions for the different CISTM13 sessions, and have worked to create a rich, diverse program that will be delivered by leading experts in the field. The response to our invitations to present at the conference has been extremely positive.

In a second meeting in Guatemala in February 2013, we had to choose from amongst a record number (over 260) of original abstract submissions the ones that would be presented as oral communications. We would like to acknowledge the hard work



of participants who submitted well-designed and creative original content. The high number and quality of the abstracts submitted, each of which was carefully read and assessed by six members of the Scientific Program Committee, resulted in adding another free communication session to the program to accommodate the excellent work. Most of the other abstracts will be presented as posters during the conference, thus providing a wide range of innovative work from around the globe.

We thank our colleagues on the SPC who contributed excellent ideas and submitted proposals for sessions and then spent many hours working closely with us to evaluate the submitted abstracts in a transparent manner. Their input contributed to the breadth and richness of the topics and content of the plenaries, symposia and workshops chosen. We extend a special thanks to all members of the Society who contributed suggestions for the different sessions. We have tried to balance the selection of topics for this conference, emphasizing new ideas while providing ample coverage of general topics that – we are sure – you would like to hear the latest news about.

The membership provides inspiration for the work of the SPC. Your contributions and thoughts enrich the Society. CISTM13 provides an opportunity for travel medicine providers to reconnect with longtime colleagues, make new contacts, exchange ideas, discuss controversial topics and, not the least, to enjoy these days and have fun. We look forward to an exciting and thought-provoking conference as we strive to improve the practice of Travel Medicine and expand and solidify its scientific base. Welcome to Maastricht!

Cheers,

Mary E. Wilson, United States of America
CISTM13 SPC Chair

Leo G. Visser, The Netherlands
CISTM13 SPC Co-Chair

Blaise Genton, Switzerland
CISTM13 SPC Associate Chair



Christina Greenaway, Canada
CISTM13 SPC Associate Chair



Organisation

The ISTM greatly appreciates the contributions of time and expertise provided by the following people to the 13th Conference of the International Society of Travel Medicine.

CISTM13 Scientific Program Committee

- Chair:** Mary E. Wilson, Washington, DC, United States
- Co-Chair:** Leo G. Visser, Leiden, The Netherlands
- Associate Chairs:** Blaise Genton, Lausanne, Switzerland
- Christina Greenaway, Montreal, Quebec, Canada
- Members:** Elizabeth D. Barnett, Boston, MA, United States
- Michele Barry, Stanford, CA, United States
- John Bosch, Terneuzen, The Netherlands
- John Christenson, Indianapolis, IN, United States
- Valérie D'Acromont, Basel, Switzerland
- Carolyn Driver, Cheshire, England, United Kingdom
- Larry Goodyer, Leicester, England, United Kingdom
- Martin P. Grobusch, Amsterdam, The Netherlands
- Eyal Leshem, Ramat Gan, Israel
- Michael Libman, Montreal, Quebec, Canada
- Poh Lian Lim, Singapore
- Anne McCarthy, Ottawa, Ontario, Canada
- Marc Mendelson, Cape Town, South Africa
- Philippe Parola, Marseille, France
- Watcharapong Piyaphanee, Bangkok, Thailand
- Edward T. Ryan, Boston, MA, United States
- Nohoko Sato, Tokyo, Japan
- Marc Shaw, Auckland, New Zealand
- Heli Siikamaki, Helsinki, Finland
- Hilary Simons, Liverpool, England, United Kingdom
- William Stauffer, St. Paul, MN, United States
- Perry J.J. van Genderen, Rotterdam, The Netherlands

CISTM13 Local Organizing Committee

- Chair:** Gerard JB Sonder, Amsterdam, The Netherlands
- Members:** Peter de Beer, Maastricht, The Netherlands
- John Bosch, Terneuzen, The Netherlands
- Steven Callens, Gent, Belgium
- Perry van Genderen, Rotterdam, The Netherlands
- Alfons Van Gompel, Antwerpen, Belgium
- Christian Hoebe, Maastricht, The Netherlands
- Michiel Laaper, Sittard, The Netherlands
- Yves Van Laethem, Brussels, Belgium
- Philippe Leonard, Luik, Belgium
- Pieter van Thiel, Amsterdam, The Netherlands



CISTM13 Oversight Committee

Chair:

- Fiona Genasi, United Kingdom
- David O. Freedman, United States of America
- Alan J. Magill, United States of America
- Gerard JB Sonder, The Netherlands
- Frank von Sonnenburg, Germany
- Diane L. Nickolson, United States of America

ISTM Executive Board

President:

- Fiona Genasi, United Kingdom

President-Elect:

- David R. Shlim, United States of America

Past-President:

- Alan J. Magill, United States of America

Counselors:

- Francesco Castelli, Italy
- Lin H. Chen, United States of America
- Karin Leder, Australia
- Annelies Wilder-Smith, Singapore

Secretary/Treasurer:

- David O. Freedman, United States of America

Executive Director:

- Diane L. Nickolson, United States of America



ISTM Executive Board from left to right.

Back row: Annelies Wilder-Smith, Alan Magill, David Shlim, David Freedman

*Front row: Karin Leder, Diane Nickolson, Fiona Genasi, Lin Chen,
Francesco Castelli*



The International Society of Travel Medicine (ISTM) is committed to the promotion of healthy and safe travel. In cooperation with health care providers, academic centers, the travel industry and the media, ISTM advocates and facilitates education, service, and research activities in the field of travel medicine. This includes: preventive and curative medicine within many specialties such as tropical medicine, infectious diseases, high altitude physiology, travel related obstetrics, psychiatry, occupational health, military and migration medicine, and environmental health.

ISTM's specific goals are to:

- ✓ promote travel health
- ✓ develop guidelines for travel medicine practice
- ✓ educate health care professionals, public health professionals, and the travel industry
- ✓ provide a scientific focus for travel medicine
- ✓ stimulate the professional advancement of travel medicine practice
- ✓ promote distribution of rapid information exchange related to travel medicine issues
- ✓ facilitate international contacts between practitioners of travel medicine
- ✓ promote development and evaluation of safe, effective, preventive and curative interventions
- ✓ foster research in travel medicine, including the promotion of international collaborative studies



International Society of Travel Medicine

Established 1991

Promoting healthy travel worldwide

ISTM Secretariat

Telephone: +1-404-373-8282 | Telefax: +1-404-373-8283

Email: ISTM@ISTM.org | Web: www.ISTM.org | Skype: [ISTM.office](https://www.skype.com/en/contacts/voice/ISTM.office)

The International Society of Travel Medicine Member Benefits Include...





The International Society of Travel Medicine
would like to thank our supporters:



Silver Level
Sponsor



Exhibitors

Bimuno[®]
Centers for Disease Control & Prevention
Crucell
GlaxoSmithKline Vaccines registered as GlaxoSmithKline Biologicals
inFact UK Ltd
International SOS
NECTM
Novartis Vaccines & Diagnostics, Inc.
Oxford University Press
Royal College of Physicians and Surgeons of Glasgow
Sanofi Pasteur MSD
Shoreland, Inc.
Sigma-Tau S.p.A.
Sitata Inc.
South African Society of Travel Medicine (SASTM)
tropimed[®]

Mark your calendars for the first joint conference of the ISTM and WMS in beautiful Jackson Hole. Join us for this historic event and explore the intersection of travel and wilderness medicine.

August 3-7, 2014

Jackson Hole, Wyoming, USA

6th Regional
Conference of the
**International
Society of
Travel Medicine**
ISTM.org



2014 Summer
Conference of the
**Wilderness
Medical
Society**
WMS.org





Descriptions of Scientific Program Sessions

Plenary Lectures

The daily plenaries during the meeting are meant to highlight areas at the forefront of travel medicine. In general these are internationally prominent invited speakers with expertise allied to travel medicine who delegates would like to hear, but who would not otherwise attend a travel medicine meeting. Each speaker is allotted 30 minutes; there is no discussion period during plenary sessions. There are no concurrent sessions running during plenaries.

Symposium Lectures

Each symposium is meant to highlight areas at the forefront of daily travel medicine practice. The topics are more focused than the plenaries and in many cases will appeal most to subsets of delegates with special interests. Each speaker is allotted 25 minutes for their presentation with 5 minutes for questions. Symposia are held concurrently with other sessions.

Workshop Sessions

Each workshop session is designed to promote dialogue between 2 experts on a topic in the field of travel medicine and individuals in practice who have experiences to share and questions to ask. While designed to be intimate and interactive, experience indicates that workshop audiences will vary. Practical information that will give participants insight into the most current strategies for prevention, self-treatment, and diagnosis is emphasized. Workshop chairs will have developed a set of clinical scenarios or case histories designed to stimulate discussion/learning. Some workshops are designated as ABC, indicating an introductory level of content, and some as Destination which focus on a particular geographic area. All workshop sessions are concurrent with other sessions.

Debate

The debate during the meeting is meant to highlight a controversial area at the forefront of travel medicine. This format will feature 2 highly experienced ISTM members who will debate specific issues under the broad topic. There will be opening and closing statements by each of the debaters, and time will be made available for questions from the audience to the debaters. This session will be held concurrently with other sessions.



Free Communications Oral Sessions

Each free communication session will consist of presentations of the latest original research, case studies, or experiences of travel medicine peers. Each presentation will be 10-minutes in length with 5 minutes for questions and discussion. These sessions are concurrent with other sessions.

Posters

Posters are presented on the latest original research, case studies or experiences of travel medicine practitioners. Posters must be displayed on Monday, 20 May by 10.00, and will be available for viewing from Monday, 20 May 2013 at 10.30 until Wednesday, 22 May 2013 in the Exhibit Hall. Authors will be in attendance on Wednesday, 22 May 2013 from 16.15 to 17.15.

Poster Tours

On Tuesday, 21 May 2013 during the morning and afternoon breaks, invited experts in travel medicine will lead groups to view posters and discuss selected topics. The poster tours are listed in the program schedules, and all delegates are invited to participate. To join a poster tour, simply go to the Exhibition at the start times indicated in the schedule. There will be signage placed near the entrance and Conference staff will make certain you find your selected tour leader.

Meet-the-History Lectures

In the early morning, the always popular Meet-the-History sessions describe historical and cultural background information on the local area that is of particular interest to travel medicine professionals.

Case of the Day

In an early morning session, an expert in travel medicine will present cases that are both interesting and informative to attending delegates. The cases will raise issues of diagnosis and therapy that will stimulate discussion and participation by those attending.

Meet the Professor

In these early morning sessions, travel medicine experts will meet with attendees to discuss professional development and career planning.



Important Information

Admittance Badges

Participants are required to wear their name badges while in attendance. Badges will be checked at the entrance of the exhibition and the scientific program meeting rooms. If you have misplaced your badge, registration staff will assist you in securing a replacement.

- Full Delegate Badge: All activities throughout the Conference
- One Day Badge: All activities on the specified day
- Accompanying Person Badge: Welcome Reception and Exhibition
- Persons not wearing a badge will be denied admission.

Photographs

Taking pictures of presenters and slides of the presentations is strictly prohibited. Only the ISTM contracted photographer may take photographs in the scientific program meeting rooms.

Speaker Abstracts

Abstracts from invited speakers, free communication and poster presenters can be found on the ISTM website at www.ISTM.org for all delegates to review and download. Once on the website click on the CISTM13 picture on the home page to access the full CISTM13 website. The link to the abstracts can be found in the navigation column on the left side of this page.

Wi-Fi Access at the Maastricht Exhibition and Conference Centre (MECC)

ISTM is delighted to be providing Wi-Fi access in the MECC free to all CISTM13 delegates. To log in, use 'CISTM13' as both your username and password when prompted.

Liability

The 13th Conference of the International Society of Travel Medicine in no event shall be liable for acts or defaults in the event of injury, damage, loss, accident, delay or irregularity of any kind whatsoever during arrangements organized through contractors or the employees of such contractors in performing services. The organizers reserve the right to make changes, where deemed necessary, without prior notice to parties concerned.



Evaluation Form

You will find an evaluation form in your conference bag. Please take a few minutes to evaluate the sessions you attend. The form can be returned to the Registration Desk.

Continuing Medical Education (CME) Credits

The '13th Conference of the International Society of Travel Medicine' is designated for a maximum of (or 'for up to') 20 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

EACCME credits

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. The EACCME credit system is based on 1 ECMEC per hour with a maximum of 3 ECMECs for half a day and 6 ECMECs for a full-day event.

Continuing Education Credits for Nurses

The Dutch Accreditation Committee grants as standard 3 accreditation points per day of attendance at CISTM13. For nurses who attend the conference on Tuesday May 21, 3 extra accreditation points will be requested to make a total of 6 points.

Accreditation for the CISTM13 is currently being sought from the American Association of Nurse Practitioners (AANP). This program is pending AANP approval at the time of printing these materials.

Accreditation Certificates

If your registration included CME or CE accreditation you should have received these materials with your registration. Please check with the registration staff if you have any questions.



Faculty Disclosures

Jesse Alves	Jeff Goad ¹¹	Marc Mendelson
Antoine Andreumont ¹	Larry Goodyer ¹²	Deborah Mills ²¹
Helena Hervius Askling ²	Martin P. Grobusch	Margot Mütsch
Satchit Balsari	Stefan Hagmann	Abdisalan Mohamed Noor
Elizabeth D. Barnett ³	Sheila C. K. Hall	Cecilia Perret ²²
Buddha Basnyat	David Hamer ¹³	Watcharapong Piyaphanee
Quique Bassat ⁴	Randi Hammer Boge	Peter M. Rabinowitz
Trish Batchelor ⁵	Stephen W. Hargarten	Jan Hindrik Ravseloot
Irmgard Bauer	Christoph Hatz ¹⁴	Julie Richards
Ron H. Behrens ⁶	Karl M. Hess ¹⁵	Gail Rosselot
Johannes Blum	David L. Heymann	Robert Sack
Andrea K. Boggild	David R. Hill	Patricia Schlagenhauf ²³
Sarah Borwein	Li Yang Hsu ¹⁶	Brian S. Schwartz
John Bosch	Nancy Piper Jenks	Eli Schwartz
Emmanuel Bottieau	Emily S. Jentes	Kevin Schwartzman
Benjamin Brenner	Michael E. Jones ¹⁷	Mary-Louise Scully
Gerd Burchard ⁷	Susan R. Kahn	Marc Shaw
Corrie C. Brown	Kevin Kain	David R. Shlim
I. Dale Carroll	Jay Keystone	Hilary Simons
Francesco Castelli	Susan Kuhn	Gerard JB Sonder
Eric Caumes ⁸	Ted Lankester	Darius Soonawala
Martin Cetron	Karin Leder ¹⁸	Mike Starr
Lin H. Chen ⁹	Peter A. Leggat ¹⁹	Robert Steffen
Jane Chiodini ¹⁰	Eyal Leshem	Perry van Genderen ²⁴
Joannes Clerinx	Claudine Leuthold	Lisette van Lieshout
Kerryann Cope	Michael Libman ²⁰	Christopher Van Tilburg
Roel Coutinho	Poh Lian Lim	Timothy Walsh
Valérie D'Acromont	Alan J. Magill	Brian Ward ²⁵
V.A.S.H. Dalm	Alberto Matteelli	Jim Waterhouse
Philippe Gautret	Anne McCarthy	Annelies Wilder-Smith
Mark Gershman	Brian McCloskey	Caroline S. Zeind
		Irina V. Zhdanova ²⁶

The footnoted Speakers have indicated that they have relationships with the entries listed below which, in the context of their presentations(s), could be perceived as a potential conflict of interest (e.g., direct research funding from a commercial organization, etc.).

1. Da Volterra Company – Honorarium; Gene-wave – collaboration with French National Agency for Innovation
2. Abbott – Honorarium for vaccine biologics; Intercell – investigator JE Vaccine; Sanofi Pasteur MSD- investigator pediatric MMR
3. Intercell – research funding; Cerexa – research funding, travel; Novartis – honorarium
4. Novartis – travel; Sigma Tau – travel and honorarium
5. GlaxoSmithKline – honorarium, speaker malaria



6. Sigma Tau, Norgine – honorarium; Intercell – research funding
7. Novartis, GlaxoSmithKline, Sigma Tau – honorarium
8. BMS, Baxter, Gallen – honorarium
9. Xcellerex Inc – research; Thompson Media LLC – honorarium; Shoreland Inc – editor for Malaria
10. GlaxoSmithKline Travel Health, Norgine, Sigma Tau – honorarium; Sanofi Pasteur MSD, Crucell Ltd – speaker fee travel health
11. Merck Vaccine, Intercell – honorarium; Merck, Intercell – speaker’s bureau for vaccines
12. Director Nomad Travel Store and Clinics; GlaxoSmithKline, Norgine, Sigma Tau – consultant
13. iJet – consultant
14. GlaxoSmithKline, Novartis – honorarium
15. Merck – vaccines speaker, speaker’s bureau for vaccines
16. Merck Sharpe & Dohme, Pfizer, Janessen & Cilag – honorarium research funding; Shoreland – honorarium
17. Merck Sharp & Dohme, GlaxoSmithKline, Gilead- Conference registration; GlaxoSmithKline – lecture
18. GlaxoSmithKline, Sanofi – travel support; GlaxoSmithKline – research support
19. CSL, Sanofi Pasteur – travel support; GlaxoSmithKline – honorarium
20. Sanofi – honorarium
21. Sanofi, GlaxoSmithKline, CSL – sponsorship of travel medicine, Alliance Group – 30 Australia, travel medicine clinics
22. Sanofi Pasteur – honorarium, registration fee and plane fare for congress
23. F. Hoffmann-La Roche – honoraria, grants, consultancy fees; GlaxoSmithKline – honoraria, grants; Sigma Tau – honoraria
24. GlaxoSmithKline – honorarium
25. Medicago Inc – consultant, stock options
26. Pfizer, Inc – research grant

ISTM Charity Donations Program

Thank you to those who have already donated to this program. It is not too late to participate in this opportunity to enhance your ability to assist the less fortunate throughout the world. For that purpose, the ISTM intends to equally match the amount donated by CISTM13 delegates to any of the charitable organizations listed below, up to an aggregate maximum ISTM contribution (for all the charities) of USD 15,000 (approximately 11,500 Euro). The eligible organizations, which focus on helping people in poorer communities in specified regions of the world, were selected based on recommendations by ISTM members. ISTM believes that each serves worthy goals, but has not conducted any detailed investigation of their operations, and is not specifically recommending or endorsing any of these organizations. You can learn about each of these organizations by visiting its website (also listed below), or making such other inquiry as you believe appropriate. The eligible organizations are:

Australian Himalayan Foundation, based in Australia serving Nepal
www.australianhimalayanfoundation.org.au

Chad Relief Foundation, based in the United States of America serving Chad
www.chadrelief.org



Mae Tao Clinic, partner with Community Partners International in the United States of America based in Burma, serving Burma

www.maetaoclinic.org

Neary Khmer, based in Cambodia serving Cambodia

www.nearykhmer.org

Vine Trust, based in Scotland serving Peru and Tanzania

www.vinetrust.org/home

ISTM makes no representations as to deductibility or other legal or tax consequences of any CISTM13 registrant's contributions to these organizations, since such matters are determined by the laws of both the recipient's location and the donor's place of tax residency, as well as the donor's personal tax and financial circumstances. Each potential donor is advised to consult with his or her financial and tax advisers to determine the consequences to him or her of such a donation.

Speaker Ready Room

The Speaker Ready Room is located at the MECC in The Madrid Room, Level 0, Room 0.6. The Speaker Ready Room hours are:

Sunday, 19 May 2013: 08.00-17.00

Wednesday, 22 May 2013: 07.00-16.00

Monday, 20 May 2013: 07.00-17.00

Thursday, 23 May 2013: 07.00-11.00

Tuesday, 21 May 2013: 07.00-17.00

Speakers can bring files on CD-Rom or a Memory Stick for uploading into the onsite audiovisual equipment. We ask that all speakers bring their presentations to the speaker ready room the day before their scheduled session, but no later than two hours prior to their scheduled session.

Welcome Reception

The Welcome Reception will take place immediately following the Opening Ceremony on Sunday, 19 May 2013 at the Exhibition located on the first level of the MECC, in the Expo Foyer from 18.00 – 20.00.

Dinner at La Caverne de Geulhem

The optional dinner has been sold out. If your registration included tickets to this dinner, you would have received them, with information regarding the shuttle service, with your registration materials. If you have any questions, please consult staff at the registration desk.



Pre CISTM Courses

The two pre-CISTM courses are being held on Sunday, 19 May from 14.00 to 16.30 at the MECC. If you registered for one of the courses, you would have received your admittance tickets when you registered. If you have any questions, please consult staff at the registration desk.

CISTM13 Onsite Registration Information

The Registration Desk is located in the Trajectum area of the MECC. Registration hours are as follows:

Saturday, 18 May 2013: 18.00-20.00

Tuesday, 21 May 2013: 08.00-17.00

Sunday, 19 May 2013: 10.00-20.00

Wednesday, 22 May 2013: 08.00-17.00

Monday, 20 May 2013: 07.00-17.00

Thursday, 23 May 2013: 08.00-14.00

International SOS Medical Opportunities for Doctors



International SOS is the world's leading provider of global medical assistance, international healthcare and security services. We have a range of opportunities including permanent residential positions in large cities or exciting opportunities in remote operational sites.

Remote Site Medical Services working with global oil, gas, mining and energy corporations in assessing the health risks of their onsite employees working in remote operational environments across Asia, Africa, Australasia and Middle East.

Global Medical Assistance

Our assistance centres are staffed by qualified medical professionals who respond to calls for assistance in the event of a medical emergency - evacuation and repatriation.

International SOS Clinics

Our clinics operate in countries where medical care of an international standard is unavailable. Our clinics offer our local and expatriate members a range of primary care, diagnostic and emergency care within a general practice setting.

To join us


To find out more information regarding the above international opportunities & to apply online go to our website at www.internationalsos.com and follow the link to the "International Medical Career Opportunities" section.



Maps of Maastricht Exhibition and Conference Centre

Plattegrond MECC Maastricht


0-niveau



T +31(0)43 383 83 83 | F +31(0)43 383 83 00 | E info@mecc.nl | I www.mecc.nl
KvK 14618216 | BTW 204181801 | Bank 57 40 30 325 | IBAN NL06ABNA0576030325 | BIC ABNANL3A



Plattegrond MECC Maastricht




T +31(0)43 383 83 83 | F +31(0)43 383 83 06 | E info@mecc.nl | www.mecc.nl
RvK 14618316 | BTW 304181201 | Bank 57 00 30 325 | IBAN NL06ABNA0570030325 | BIC ABNANL2A



Plattegrond MECC Maastricht

2-niveau



T +31(0)43 383 83 85 | F +31(0)43 383 83 00 | E info@mecc.nl | www.mecc.nl
KvK 14618316 | BTW 304181201 | Bank 57 00 30 323 | IBAN NL94ABNA0579030325 | BIC ABNANL2A

The 14th Conference of the International Society of Travel Medicine

24-28 May 2015

Québec City, Canada



International Society of Travel Medicine

Promoting healthy travel worldwide

Established 1991

www.istm.org

Early Registration: 31 December 2014

Abstract Submission: 7 January 2015



CISTM13 Opening Ceremony

Auditorium, MECC

19 May 2013

17.00-18.00

Chairs: **Fiona Genasi**, President of the ISTM
Gerard JB Sonder, CISTM13 Local Organizing Committee Chair

- 17.00-17.05** | **Welcome to the CISTM13**
Fiona Genasi, ISTM President
- 17.05-17.10** | **Welcome to the Netherlands and Belgium**
Gerard JB Sonder, Chair LOC
- 17.10-17.20** | **Welcome to Maastricht**
Theo Bovens, King's Commissioner for the Province of Limburg
- 17.20-17.35** | **Entertainment**
De Nachtwacht
- 17.35-17.40** | **The CISTM13 Scientific Program**
Mary E. Wilson, CISTM13 Scientific Program Committee Chair
- 17.40-18.00** | **Keynote Speaker**
David Overbosch: Infectious Diseases and Art
- 18.00-18.05** | **Closing Remarks**
Gerard JB Sonder, CISTM13 LOC Chair



Immediately following the Opening Ceremony the Welcome Reception will be held in the Expo Foyer of the MECC.

Welcome to Maastricht!





CISTM13 Program Schedule

All sessions held in the Maastricht Exhibition and Conference Centre (MECC).

Time	Program	Location
Sunday 19 May 2013		
14.00-16.30	Pre CISTM Course 1 Psychological Issues in International Travel: All you Need to Know	Athens, Level 0 Room 0.9
	Pre CISTM Course 2 Responsible Travel: A Travel Health Concern?	Rome, Level 0 Room 0.8
15.00-16.30	Nurses Reception	Brussels/Paris, Level 0 Rooms 0.4/0.5
15.00-16.30	Pharmacists Reception	Pressroom, Level 0 Room 0.11
17.00-18.00	Opening Ceremony	Auditorium, Level 1
18.00-20.00	Welcome Reception	Exhibition, Level 1



Time	Program	Location
Monday 20 May 2013		
MTH1 08.00-08.45	Meet The History 1 From House of God to Academic Hospital: The History of Medicine in Maastricht H.F.P Hillen , The Netherlands	Paris, Level 0 Room 0.5
COD1 08.00-08.45	Case of the Day 1 Vanessa Field , United Kingdom	Rome, Level 0 Room 0.8
MTP1 08.00-08.45	Meet the Professor 1 Mentorship Michele Barry , United States of America	Athens, Level 0 Room 0.9





Time	Program	Location
Monday 20 May 2013, continued		
PL1 09.00-10.30	<p>Plenary 1 Antibiotic Resistance: Mobile Bugs in a Connected World <i>Chairs: Leo G. Visser, The Netherlands</i> <i>Mary E. Wilson, United States of America</i></p> <p>PL1.1 <i>Overview, Mechanisms, Example of Delhi NDM1 Spread</i> Timothy Walsh, United Kingdom</p> <ul style="list-style-type: none"> • Understand three ways bacteria can become resistant to antibiotics, and how the movement of genetic elements confers resistance among bacteria. • Learn two factors that have enabled the spread of bacteria with NDM-1. <p>PL1.2 <i>Travelling Golden Staphylococci</i> Li Yang Hsu, Singapore</p> <ul style="list-style-type: none"> • Understand three consequences of staphylococcal infections by travellers. • Learn the role of travellers in the movement of staphylococci and resistance elements across populations. • Learn the drivers of resistance, including the use of antimicrobials in animals. <p>PL1.3 <i>Acquisition, Colonization and Spread by Unsuspecting Travellers</i> Antoine Andremont, France</p> <ul style="list-style-type: none"> • Understand the three ways to reduce the development and spread of resistant bacteria. • Understand the ecology of resistance. • Learn the identification, monitoring, and control of resistance. • Learn about the persistence and movement of elements conferring resistance in colonizing bacteria. 	Auditorium, Level 1
10.30-11.15	Morning Break	Exhibition, Level 1



Time	Program	Location
Monday 20 May 2013, continued		
SY1 11.15-12.45	<p>Symposium 1 Jet Lag Chronobiology, Travel and Treatment <i>Chairs: Lin H. Chen, United States of America</i> <i>Louis Loutan, Switzerland</i></p> <p>SY1.1 <i>The Circadian Clock and Time Zone Travel</i> Irina V. Zhdanova, United States of America</p> <ul style="list-style-type: none"> • Review circadian system and how it responds to time shift. • Review why we develop jet lag syndrome and how it differs from other forms of desynchrony. <p>SY1.2 <i>Maximizing Performance Across Time Zones</i> Jim Waterhouse, United Kingdom</p> <ul style="list-style-type: none"> • Review pros and cons of light therapy, behaviour modifications, diet and exercise, napping and other actions that individual travellers could initiate as non-pharmacologic interventions. <p>SY1.3 <i>Pharmacotherapy</i> Robert Sack, United States of America</p> <ul style="list-style-type: none"> • Review evidence that various pharmacologic agents work for jet lag syndrome. • Review pros and cons of melatonin, caffeine, hypnotics. 	Auditorium, Level 1
FC1 11.15-12.45	<p>Free Communication 1 All About Malaria <i>Chairs: Jeff Goad, United States of America</i> <i>Pieter van Theil, The Netherlands</i></p>	Paris, Level 0, Room 0.5
11.15-11.30	<p>FC1.1 <i>Malaria Knowledge and Use of Malaria Prevention in the UK Population and in UK Passengers Departing to Malaria Endemic Areas.</i> Ron H. Behrens, United Kingdom</p>	
11.30-11.45	<p>FC1.2 <i>Eye Disorders Reported with the Use of Mefloquine Chemoprophylaxis – a Drug Safety Database Analysis</i> Patricia Schlagenhauf, Switzerland</p>	



Time	Program	Location
Monday 20 May 2013, continued		
11.45-12.00	<p>FC1.3 <i>Acute Malaria Infections Despite a Complete or Abbreviated Chemoprophylactic Regimen of Atovaquone-proguanil</i> Paul M. Arguin, United States of America</p>	
12.00-12.15	<p>FC1.4 <i>How did Travellers Use During their Trip Rapid Diagnostic Test for Malaria Provided by a Travel-clinic?</i> Delphine Berthod, Switzerland</p>	
12.15-12.30	<p>FC1.5 <i>Artemether-Lumefantrine Compared to Atovaquone-Proguanil as a Treatment for Plasmodium falciparum Malaria in Travelers</i> Tamar Lachish, Israel</p>	
12.30-12.45	<p>FC1.6 <i>Safety of Antimalarials in the Treatment of Severe Imported Malaria - a Single-centre Retrospective Study.</i> Thierry Rolling, Germany</p>	
WS1 11.15-12.45	<p>Workshop 1 Would You Vaccinate this Traveller: Yellow Fever Vaccine Cases Mark Gershman, United States of America Christoph Hatz, Switzerland</p> <ul style="list-style-type: none"> • 3-4 case studies will be discussed and essential criteria to consider in deciding on the appropriateness of prescribing yellow fever vaccination will be highlighted. Case studies will address yellow fever vaccination recommendations and country entry requirements, as well as medical contraindications and precautions to vaccination. 	Rome, Level 0 Room 0.8





Time	Program	Location
Monday 20 May 2013, continued		
<p>SY2 11.15-12.45</p>	<p>Symposium 2 One World: Migrants and Health <i>Chairs: Francesco Castelli, Italy</i> <i>Jose Flores-Figueroa, Mexico</i></p> <p>SY2.1 BioMosaic Martin Cetron, United States of America</p> <ul style="list-style-type: none"> Review the magnitude and growth of global migration and its impact on human health. Describe The BioMosaic Project and present its objectives and application to public health and travel medicine. <p>SY2.2 Accessing VFR Populations for Public Health Messages Peter A. Leggat, Australia</p> <ul style="list-style-type: none"> Review the travel health risks related to VFR travel. Describe novel approaches to engaging immigrant communities to access and promote pre-travel advice in the VFR population. <p>SY2.3 Approach to Migrants Upon Arrival Anne McCarthy, Canada</p> <ul style="list-style-type: none"> Review the health status of migrants and predictors for poor health outcomes. Present an overview of the recently published Canadian Collaboration for Immigrant and Refugee Health (CCIRH) guidelines as an example of an approach to health promotion post-arrival and describe applications of this to travel health. 	<p>Brussels, Level 0 Room 0.4</p>





Time	Program	Location
Monday 20 May 2013, continued		
WS2 11.15-12.45	Workshop 2 The Anticoagulated Traveller: Issues and Answers Michael Libman , Canada Susan Kahn , Canada Perry van Genderen , The Netherlands <ul style="list-style-type: none"> • Review the risk and associated challenges of travel while taking anticoagulants. • Discuss practical strategies of how to manage anticoagulation medications during travel including adjusting doses, avoid drug interactions, etc. 	Athens, Level 0 Room 0.9
12.45-14.45	Lunch Break	Exhibition, Level 1
SY3 14.45-16.15	Symposium 3 Risk: Perceived vs. Real, and Communication Tools <i>Chairs:</i> Charles D. Ericsson , United States of America Annelies Wilder-Smith , Singapore SY3.1 Perceived versus Actual Risk Ron H. Behrens , United Kingdom <ul style="list-style-type: none"> • Review estimated risk for different diseases and different destination according to travel information. • Discuss the perceived risk for the same diseases and destination. • Explain the reasons for these differences. SY3.2 Helping the Professional Understand Risk Concepts Karin Leder , Australia <ul style="list-style-type: none"> • Review the determinants of risk and how it is calculated. • Describe the pitfalls to estimate risk in travel medicine. • Give examples on how health professionals can better understand risk. SY3.3 Helping the Professional Communicate Risk Jane Chiodini , United Kingdom <ul style="list-style-type: none"> • Describe how actual risk can be appropriately communicated to a lay person and give examples. • Illustrate how different means can lead to different uptake of preventive measures. 	Auditorium, Level 1



Time	Program	Location
Monday 20 May 2013, continued		
SY4 14.45-16.15	<p>Symposium 4 New and Emerging Bugs and Travel: Tryps, TB, and Fungi <i>Chairs:</i> Christoph Hatz, Switzerland Shuzo Kanagawa, Japan</p> <p>SY4.1 Trypanosomiasis Joannes Clerinx, Belgium</p> <ul style="list-style-type: none"> • Review briefly the epidemiology, clinical manifestations and diagnostic criteria for trypanosomiasis. • Illustrate by the description of cases of imported trypanosomiasis and why it has been (or not been) suspected. <p>SY4.2 MDR, XDR, TDR-TB Martin P. Grobusch, The Netherlands</p> <ul style="list-style-type: none"> • Review briefly the epidemiology, risk factors and criteria to diagnose MDR, XDR, TDR-TB. • Describe the different therapies available and their effectiveness. • Assess the risk for the traveller. <p>SY4.3 Fungal Infections in Travellers Eli Schwartz, Israel</p> <ul style="list-style-type: none"> • Review briefly the epidemiology, risk factors and procedures to diagnose the most prevalent. • Give some examples of these with pictures and review the treatment. 	Brussels, Level 0 Room 0.4
WS3 14.45-16.15	<p>Workshop 3 High Altitude Travel Buddha Basnyat, Nepal Alan J. Magill, United States of America</p> <ul style="list-style-type: none"> • Discuss health problems at high altitude and pathophysiology. • Discuss pharmacological and behavioural interventions. • Discuss high risk travellers and itineraries. 	Paris, Level 0 Room 0.5



Time	Program	Location
Monday 20 May 2013, continued		
WS4 14.45-16.15	Workshop 4 Seeking Answers: Resources for Travel Medicine (ABC) David Hamer , United States of America Claudine Leuthold , Switzerland <ul style="list-style-type: none"> • Know where to find background information on country, security, maps, disability, and evacuation. • Use surveillance and epidemiological data. • Apply different sources of travel medicine recommendations. • Appraise travel warnings and consular information. • Use vaccine resources. 	Rome, Level 0 Room 0.8
FC2 14.45-16.15	Free Communication 2 Special Needs (Mental Health and Immunosuppression) <i>Chairs:</i> Michael E. Jones , United Kingdom Thomas Valk , United States of America	Athens, Level 0 Room 0.9
14.45-15.00	FC2.1 <i>Mental Health and Study Abroad: Incidence and Mitigation Strategies</i> Ryan Copeland , United States of America	
15.00-15.15	FC2.2 <i>Japanese Encephalitis Vaccine Administration Practices Among U.S. Travel Medicine Practices in Global TravEpiNet</i> Regina C. LaRocque , United States of America	
15.15-15.30	FC2.3 <i>The Traveling-Travel Clinic: Improving Access for Visiting Friends and Relative Travelers, Hajj Clinic Pilot Project.</i> Gregory Carlson , United States of America	
15.30-15.45	FC2.4 <i>Immune Response to Combined Hepatitis A and B Vaccine in HIV-infected Children or Children on Immunosuppressive Medication in Juvenile Idiopathic Arthritis in Contrast to Healthy Children: A Substantial Proportion Not Immune for Hepatitis A after First Vaccination</i> Gerard JB Sonder , The Netherlands	



Time	Program	Location
Monday 20 May 2013, continued		
15.45-16.00	FC2.5 <i>International Travel Patterns and Travel Risks of Stem Cell Transplant Recipients</i> Tarek Mikati , United States of America	
16.00-16.15	FC2.6 <i>Epidemiology and Treatment of Hydatid Cyst in the AMC</i> Cornelis Stijnis , The Netherlands	
16.15-17.00	Afternoon Break	Exhibition, Level 1
SY5 17.00-18.30	Symposium 5 Who Should be Vaccinated? Difficult Vaccine Decisions: Yellow Fever, Rabies, and Influenza <i>Chairs:</i> Marc Mendelson , South Africa Gary Brunette , United States of America SY5.1 Rabies Philippe Gautret , France <ul style="list-style-type: none"> • Review current controversies about the use of rabies vaccine. • Understand the pros and cons of using vaccine (or RIG or a specific dose or route) in each situation. SY5.2 Yellow Fever Elizabeth D. Barnett , United States of America <ul style="list-style-type: none"> • Review the current controversies about the use of yellow fever vaccine. • Understand the data to support use or non-use of vaccine in each situation. SY5.3 Influenza Margot Mütsch , Switzerland <ul style="list-style-type: none"> • Current controversies about use of influenza vaccine in individuals and populations. 	Auditorium, Level 1



Time	Program	Location
Monday 20 May 2013, continued		
17.00-18.30	Panel Discussion Filling the Gaps in the Knowledge Base: Research Priorities in Travel Medicine <i>Chairs:</i> Michele Barry , United States of America Ron H. Behrens , United Kingdom <i>Panelists:</i> Nancy Piper Jenks , United States of America Kevin Kain , Canada Annelies Wilder-Smith , Singapore <ul style="list-style-type: none"> • Each presenter will present her (his) own view on the two main gaps in knowledge in the travel medicine field and the best study design to address those. • A discussion with presenters and audience will follow. 	Brussels, Level 0 Room 0.4
WS5 17.00-18.30	Workshop 5 Refresh! What's New in Travel and Tropical Medicine Literature Gerd Burchard , Germany Mary-Louise Scully , United States of America <ul style="list-style-type: none"> • Describe the results of new studies or observations within the past two years that affect recommendations in travel medicine. • Explain how these new findings can be integrated into the practice of travel medicine. 	Paris, Level 0 Room 0.5
WS6 17.00-18.30	Workshop 6 Safe and Intact: Safety, Security, and Injury During Travel Stephen W. Hargarten , United States of America Marc Shaw , New Zealand <ul style="list-style-type: none"> • Review the safety, security and injury risks related to travel. • Discuss practical strategies to decrease risk and to remain safe and secure during travel. 	Rome, Level 0 Room 0.8
FC3 17.00-18.30	Free Communication 3 Health Problems in Returning Travellers <i>Chairs:</i> Kenneth Dardick , United States of America Alfons van Gompel , Belgium	Athens, Level 0 Room 0.9



Time	Program	Location
Monday 20 May 2013, continued		
17.00-17.15	FC3.1 <i>Health Problems During and After Travel among Boston-Area International Travellers</i> Lin H. Chen , United States of America	
17.15-17.30	FC3.2 <i>Travel Acquired Infections and Illnesses in Canadians: Surveillance Report from CanTravNet Surveillance Data, 2009–2011</i> Andrea K. Boggild , Canada	
17.30-17.45	FC3.3 <i>High Acquisition Rates of Extended Spectrum β-Lactamase Producing Enterobacteriaceae among Dutch Travelers</i> Jessica A. Vlot , The Netherlands	
17.45-18.00	FC3.4 <i>The Changing Epidemiology of Human African Trypanosomiasis among Patients from Non-Endemic Countries, 1902-2012</i> Ami Neuberger , Israel	
18.00-18.15	FC3.5 <i>Acute Hepatitis in Israeli Travellers</i> Tamar Lachish , Israel	
18.15-18.30	FC3.6 <i>Different Etiologies of Creeping Dermatitis in 70 Consecutive Patients</i> Eric Caumes , France	
18.30-19.15	Special Update Highlights from the New Editions, WHO and CDC Gilles Pומרol , WHO, Switzerland Gary Brunette , CDC, United States of America	Brussels, Level 0 Room 0.4
18.30-19.15	ISTM Pediatric Interest Group General Assembly	Paris, Level 0 Room 0.5
18.30-19.15	ISTM Destination Communities Support Interest Group General Assembly	Rome, Level 0 Room 0.8
18.30-19.15	ISTM Psychological Health of Travellers Interest Group General Assembly	Athens, Level 0 Room 0.9



Time	Program	Location
Tuesday, 21 May 2013		
MTH2 08.00-08.45	Meet the History 2 Malaria in Belgium, The Netherlands, and Elsewhere in Europe: A Forgotten History! Marc Coosemans, Belgium	Paris, Level 0 Room 0.5
COD2 08.00-08.45	Case of the Day 2 Prativa Pandey, Nepal	Rome, Level 0 Room 0.8
MTP2 08.00-08.45	Meet the Professor 2 Abstract Writing Charles D. Ericsson, United States of America Anu Kantele, Finland	Athens, Level 0 Room 0.9





Time	Program	Location
Tuesday, 21 May 2013, continued		
PL2 09.00-10.30	<p data-bbox="258 328 807 352">Plenary 2</p> <p data-bbox="258 357 807 381">Malaria: From Research to Recommendation</p> <p data-bbox="258 386 807 410">Chairs: Blaise Genton, Switzerland</p> <p data-bbox="258 414 807 438">Peter A. Leggat, Australia</p> <p data-bbox="258 448 807 499">PL2.1 <i>Malaria Maps: Relevance for Travel Recommendations</i></p> <p data-bbox="258 504 807 528">Abdisalan Mohamed Noor, Kenya</p> <ul data-bbox="258 533 807 735" style="list-style-type: none"> • Description of the process to build malaria maps and the dynamics of update. • Give examples of malaria maps freely available on the internet. • Discussion of which kind of malaria maps and how they could be useful to update travel recommendations (EIR, Pf prevalence etc.). <p data-bbox="258 746 807 770">PL2.2 <i>Artemisinin Derivatives for all Malaria</i></p> <p data-bbox="258 775 807 799">Quique Bassat, Spain</p> <ul data-bbox="258 804 807 1034" style="list-style-type: none"> • Description of the results of efficacy and effectiveness trials of ACT for species other than Plasmodium falciparum in endemic areas of Asia and Oceania. • Discussion of the comparative advantages of the different ACT marketed in the US and Europe for species other than falciparum. • Description of the procedures in practice (including the use of primaquine.) <p data-bbox="258 1045 807 1069">PL2.3 <i>Diagnosis of Imported Malaria: Beyond Microscopy</i></p> <p data-bbox="258 1074 807 1098">Valérie D’Acremont, Switzerland</p> <ul data-bbox="258 1102 807 1332" style="list-style-type: none"> • Review the results of meta-analyses and studies that assessed performance of RDT in endemic and non-endemic areas and explain the pitfalls in these evaluations. • Description of the safety and usefulness of RDT in non-endemic settings. • Description of the procedures for RDT selection and implementation in non-endemic settings. 	Auditorium, Level 1



Time	Program	Location
Tuesday, 21 May 2013, continued		
10.30-11.15	Morning Break Poster Tours <i>(Meet Tour Leaders at Entrance of Exhibition)</i> Enteric Infections Edward T. Ryan , United States of America Malaria William Stauffer , United States of America Pre-Travel Advice Carolyn Driver , United Kingdom	Exhibition, Level 1
SY6 11.15-12.45	Symposium 6 Immunosuppressed Travellers: Safe Preparation Chairs: Bradley Connor , United States of America Karin Leder , Australia SY6.1 Standard Immunosuppressive Drugs V.A.S.H. Dalm , The Netherlands <ul style="list-style-type: none"> Classify immunosuppressive therapies commonly used in organ transplantation according to their site of action. Outline the effect of immunosuppressive therapies on primary and secondary immune responses to vaccines. SY6.2 Biologic Agents Helena Hervius Askling , Sweden <ul style="list-style-type: none"> Explain the effect of structure and composition of monoclonal antibodies on half life. Distinguish between depleting (cytotoxic) and non-depleting monoclonal antibodies. Predict the effect anti-TNF monoclonal antibodies on primary and secondary immune response to (travel) vaccines. Predict the effect of rituximab on primary and secondary immune response to (travel) vaccines. SY6.3 Immunosuppressive Disease Brian S. Schwartz , United States of America <ul style="list-style-type: none"> Describe types of immunosuppressive diseases. Outline implications for susceptibility to travel-related diseases. Outline implication for response to vaccines (safety and effectiveness). 	Auditorium, Level 1



Time	Program	Location
Tuesday, 21 May 2013, continued		
SY7 11.15-12.45	Symposium 7 Keeping Kids Healthy During Travel <i>Chairs: Philip R. Fischer, United States of America</i> <i>Eli Schwartz, Israel</i>	Brussels, Level 0 Room 0.4
	SY7.1 High Risk Itineraries in Under 5s (includes VFR) Susan Kuhn, Canada <ul style="list-style-type: none"> Review the health risks of young infants and children travelling to high-altitude destinations, malaria-endemic regions etc. Discuss the approach to and efficacy of decreasing health risks in these young travellers. 	
	SY7.2 Diarrhoea in Child Travellers Eyal Leshem, Israel <ul style="list-style-type: none"> Discuss the epidemiology and specific risk factors for travel associated diarrhoea in young children. Discuss the approach to prevention and management of diarrhoea in young children. Discuss the pros and cons of empiric antibiotic use and the different choices of antibiotics in young children. 	
FC4 11.15-12.45	SY7.3 Use of Newer Vaccines in Children Stefan Hagmann, United States of America <ul style="list-style-type: none"> Review the epidemiology of specific travel vaccine preventable disease in young children including meningococcus, hepatitis A, yellow fever and Japanese encephalitis. Review which young travellers should receive these vaccines and under what circumstances. Highlight the specific challenges, limitations and controversies in providing these vaccines to young children. 	Paris, Level 0, Room 0.5
	Free Communication 4 Pre-Travel Practice <i>Chairs: Nancy Piper Jenks, United States of America</i> <i>Joseph Torresi, Australia</i>	



Time	Program	Location
Tuesday, 21 May 2013, continued		
11.15-11.30	<p>FC4.1 <i>Knowledge, Attitudes and Practices of U.S. Practitioners Who Provide Pre-Travel Advice: Differences between Primary Care Providers and Travel Medicine Specialists</i></p> <p>David Hamer, United States of America</p>	
11.30-11.45	<p>FC4.2 <i>Malaria: Are Pharmacists Sufficiently Prepared to Assess and Manage Prevention Strategies?</i></p> <p>Adrienne Willcox, United Kingdom</p>	
11.45-12.00	<p>FC4.3 <i>Pre-Travel Health Care of Immigrants Returning Home to Visit Friends and Relatives</i></p> <p>Regina C. LaRocque, United States of America</p>	
12.00-12.15	<p>FC4.4 <i>Characteristics, Preferences and Decision Needs of Travellers to Countries with Risk of Yellow Fever: Implications for Healthcare Providers</i></p> <p>Lin H. Chen, United States of America</p>	
12.15-12.30	<p>FC4.5 <i>Evaluation of Vaccination Coverage in Travellers to a Yellow Fever Endemic Area (Senegal) for a Stay</i></p> <p>Christophe Rapp, France</p>	
12.30-12.45	<p>FC4.6 <i>Malaria and Yellow Fever Prevention Advice Provided by Travel Agency Employees in Cusco – Peru</i></p> <p>Miguel M. Cabada, Peru</p>	
WS7	<p>Workshop 7</p> <p>Exotic Asia: Mekong Delta/Burma (Destination)</p> <p>Trish Batchelor, Australia</p> <p>Watcharapong Piyaphanee, Thailand</p> <ul style="list-style-type: none"> • Describe of features of the region, including environment and the people. • Describe the major health and security threats to travellers. 	<p>Rome, Level 0</p> <p>Room 0.8</p>



Time	Program	Location
Tuesday, 21 May 2013, continued		
WS8 11.15-12.45	Workshop 8 How to Start a Travel Clinic (ABC) John Bosch , The Netherlands Gail Rosselot , United States of America <ul style="list-style-type: none"> • Review of strategic planning for travel clinic development, international differences to consider when establishing a travel clinic, suggestions for marketing, and promoting best practices in your clinic. • Review of text and internet resources for clinic start-up: CDC, ISTM, IAC, Dutch, other international resources and selected travel medical texts. 	Athens, Level 0 Room 0.9
12.45-14.45	Lunch Break	Exhibition Level 1





Time	Program	Location
Tuesday, 21 May 2013, continued		
SY8 14.45-16.15	<p>Symposium 8 Easy to Prevent But Still Here: Measles, Pertussis, Polio <i>Chairs:</i> Elizabeth D. Barnett, United States of America Poh Lian Lim, Singapore</p> <p>SY8.1 <i>The Spread of Measles to and from Europe and Beyond: Implications for Global Travel</i> David R. Hill, United States of America</p> <ul style="list-style-type: none"> • Describe the recent resurgence and outbreaks of measles and the role of travel in its spread. • Review the implications of the changing epidemiology of measles for the traveller and for prevention. <p>SY8.2 <i>Worldwide Resurgence of Bordetella Pertussis – Addressing a Public Health Concern</i> Mike Starr, Australia</p> <ul style="list-style-type: none"> • Describe the recent resurgence and outbreaks of pertussis and efforts that have been made to control its spread. • Review the implications of the changing epidemiology of pertussis for the traveller and opportunities for prevention. <p>SY8.3 <i>Polio</i> David L. Heymann, United Kingdom</p> <ul style="list-style-type: none"> • Describe the past and present history of the polio eradication program and highlight the successes achieved and the challenges encountered. • Review the implications of global travel in the eradication efforts for polio. 	Auditorium, Level 1






Time	Program	Location
Tuesday, 21 May 2013, continued		
WS9 14.45-16.15	Workshop 9 How to Prevent and Manage Acute and Chronic Diarrhoea in Travellers David R. Shlim , United States of America Darius Soonawala , The Netherlands <ul style="list-style-type: none"> • Recognize the clinical presentation of new causative agents of traveller's diarrhoea. • Translate knowledge on increasing resistance to anti-microbial treatment of traveller's diarrhoea into practice. • Critically appraise the need for stand-by treatment. • Discuss the diagnostic work-up of chronic diarrhoea. 	Paris, Level 0 Room 0.5
SY9 14.45-16.15	Symposium 9 Virtual Tools in Travel Medicine <i>Chairs:</i> Peter A. Leggat , Australia Anne McCarthy , Canada SY9.1 Social Media in the Practice of Travel Medicine Deborah Mills , Australia <ul style="list-style-type: none"> • Available and possible platforms for interaction with the traveller including twitter, facebook, linkedin. • The learner will be able to instruct travellers on social modalities that are accessible during travel. SY9.2 Development of In-Travel Surveillance Methods Emily S. Jentes , United States of America <ul style="list-style-type: none"> • Review existing tools for monitoring travel morbidity while on a trip. • Discuss web-based, cell phone based and tablet based methodologies in development to monitor travellers for trip associated illness. SY9.3 Support for Travellers Abroad by the Travel Clinic Kerryann Cope , United Kingdom <ul style="list-style-type: none"> • Discuss and review pros and cons of e-mail, telephone, web-based support for acute and chronic medical problems while overseas. • Modalities for ongoing delivery of wellness messages for the traveller. • Online personal health spaces to support resilience during overseas travel and postings. 	Brussels, Level 0 Room 0.5



Time	Program	Location
Tuesday, 21 May 2013, continued		
FC5 14.45-16.15	Free Communication 5 Chronic Infections in Migrants <i>Chairs: Masatoki Adachi, Japan</i> <i>Rogelio López-Vélez, Spain</i>	Rome, Level 0 Room 0.8
14.45-15.00	FC5.1 <i>Barriers to the Provision of Pre-Travel Preventative Health Advice in Primary Care to Australian Travellers Visiting Friends and Relatives</i> Bradley L. Forssman, Australia	
15.00-15.15	FC5.2 <i>Situational Analysis of HIV Travel Restrictions for Migrants</i> Annelies Wilder-Smith, Singapore	
15.15-15.30	FC5.3 <i>Clinical and Epidemiological Profile of HIV Infection among Migrant vs Italian Patients in Seven Italian Centers between 2000 and 2011</i> Giorgia Sulis, Italy	
15.30-15.45	FC5.4 <i>Prevalence of Chronic Hepatitis B Virus Infection in African Immigrants seen at a U.S. Urban Travel Health Center</i> Stefan Hagmann, United States of America	
15.45-16.00	FC5.5 <i>Hepatitis B and Migrants: Should We Do Better?</i> Manon Jaboyedoff, Switzerland	
16.00-16.15	FC5.6 <i>Screening for Chagas Disease in Switzerland: One Size Fits All?</i> Valérie D'Acremont, Switzerland	





Time	Program	Location
Tuesday, 21 May 2013, continued		
WS10 14.45-16.15	Workshop 10 Safe Transport: Carrying Meds and Needles and Accessing Medications Abroad Jeff Goad , United States of America Larry Goodyer , United Kingdom <ul style="list-style-type: none"> • Formulate recommendations how to keep drugs cool during travel. • Outline rules and regulations on travelling with medication. • Explain how to carry sharps safely with you. • Discuss access of medication abroad. 	Athens, Level 0 Room 0.9
16.15-17.00	Afternoon Break Poster Tours <i>(Meet Tour Leaders at Entrance of Exhibition)</i> Migrants Louis Loutan , Switzerland Returning Travellers Christina Greenaway , Canada Vaccines Ursula Wiedermann , Austria	Exhibition, Level 1
SY10 17.00-18.30	Symposium 10 Who Is Giving Travel Advice? An International, Multi-Professional Perspective <i>Chairs:</i> Lee Baker , South Africa Fiona Genasi , United Kingdom SY10.1 Physician Perspective Gerard JB Sonder , The Netherlands SY10.2 Nurse Perspective Sheila C. K. Hall , United Kingdom SY10.3 Pharmacist Perspective Karl M. Hess , United States of America <ul style="list-style-type: none"> • Review travel health care provision internationally from the perspective of 3 different professional groups. • Debate the relative strengths, weaknesses, opportunities, and threats that these 3 groups face when providing travel health services. 	Auditorium, Level 1



Time	Program	Location
Tuesday, 21 May 2013, continued		
WS11 17.00-18.30	Workshop 11 Preventing Malaria: Common Problems, Possible Solutions Lin H. Chen , United States of America Patricia Schlagenhauf , Switzerland <ul style="list-style-type: none"> • 3-4 case studies will be discussed. Malaria prevention in infants (repellents and chemoprophylaxis), in long-term residents (+LLIN), and pregnant women will be discussed. 	Brussels, Level 0 Room 0.4
FC6 17.00-18.30	Free Communication 6 Immunizations: Safety, Immunogenicity and Availability <i>Chairs:</i> Anthony Gherardin , Australia Elaine Rosenblatt , United States of America	Paris, Level 0 Room 0.5
17.00-17.15	FC6.1 <i>Safety and Efficacy of a Patch Containing Heat-labile Toxin from Enterotoxigenic Escherichia coli (ETEC) Against Diarrhoea in Traveler's to Mexico / Guatemala: A Randomized, Double-blind, Placebo-Controlled Phase 3 Trial</i> Ron H. Behrens , United Kingdom	
17.15-17.30	FC6.2 <i>Tick-borne Encephalitis: Long-term Follow-up and Effect of Immunity against Japanese Encephalitis and Yellow Fever</i> Herwig Kollaritsch , Austria	
17.30-17.45	FC6.3 <i>Immunity after Yellow Fever Vaccination in Travellers Using Immunosuppressive Medication</i> Rosanne W. Wieten , The Netherlands	
17.45-18.00	FC6.4 <i>Seroconversion after Fendrix Hepatitis B Vaccination in 60 Non-responders</i> Rosanne W. Wieten , The Netherlands	



Time	Program	Location
Tuesday, 21 May 2013, continued		
18.00-18.15	FC6.5 <i>Initial Neutralising Antibody Response on Day 35 after Two Different Intradermal Rabies Pre-exposure Vaccination Schedules: Preliminary Unpooled Data of a Large Prospective Clinical Trial on Rabies Boostability</i> Patrick Soentjen , Belgium	
18.15-18.30	FC6.6 <i>The Global Availability of Rabies Immune Globulin and Rabies Vaccine: A Survey of U.S. Embassy Medical Personnel</i> Emily S. Jentes , United States of America	
17.00-18.30	Debate Clots or Shots: Heparin for Travellers, Pro and Con Pro: Susan Kahn , Canada Con: Benjamin Brenner , Israel Moderator: Alan J. Magill , United States of America <ul style="list-style-type: none"> Review the epidemiology and risk factors for clotting during travel and different therapeutic options for prevention. Present the pros and cons of providing heparin pre-travel to prevent thrombosis and embolism. 	Rome, Level 0 Room 0.8
WS12 17.00-18.30	Workshop 12 Safe Shots: Practical Aspects of Vaccine Administration (ABC) Julie Richards , United States of America Hilary Simons , United Kingdom <ul style="list-style-type: none"> Review basic information about vaccine storage, handling and administration, including length of needles; simultaneous injections; administration to special populations (e.g., post mastectomy; anticoagulated); avoiding syncope after injections. 	Athens, Level 0 Room 0.9
18.30-19.15	ISTM Migrant and Refugee Special Interest Group General Assembly	Paris, Level 0, Room 0.5
18.30-19.15	ISTM Nursing Professional Group General Assembly	Rome, Level 0 Room 0.8
18.30-19.15	ISTM Pharmacist Professional Group General Assembly	Athens, Level 0 Room 0.9



Time	Program	Location
Wednesday, 22 May 2013		
MTH3 08.00-08.45	<p>Meet the History 3 History of Verenigde Oostindische Compagnie (VOC) or The Dutch East India Company Otto Bleker, The Netherlands</p> <ul style="list-style-type: none"> • The VOC or Dutch East India Company, established in 1602 by the States General of Holland, had a monopoly to carry out commercial, political and military activities in Asia. Between 1602 and 1796 it sent almost a million Europeans on 4785 ships and netted more than 2.5 million tons of Asian trade goods. • The medical service of the VOC will be discussed; especially the ship's surgeons in the eighteenth century. 	Paris, Level 0, Room 0.5
COD3 08.00-08.45	<p>Case of the Day 3 Philip R. Fischer, United States of America</p>	Rome, Level 0 Room 0.8
MTP3 08.00-08.45	<p>Meet the Professor Session Cancelled</p>	Athens, Level 0 Room 0.9





Time	Program	Location
Wednesday, 22 May 2013, continued		
PL3 09.00-10.30	<p>Plenary 3 One Health: Travellers and Zoonoses <i>Chairs: David O. Freedman, United States of America</i> <i>Christina Greenaway, Canada</i></p> <p>PL3.1 Zoonoses in a Global World Roel Coutinho, The Netherlands</p> <ul style="list-style-type: none"> • Describe how emerging infections are linked to increasing contact between humans and wildlife. • Describe how global trade/travel exacerbates the problem of zoonotic disease emergence: SARS etc. <p>PL3.2 One Health: Clinical Implications for Travel Medicine Peter M. Rabinowitz, United States of America</p> <ul style="list-style-type: none"> • Review the origin and objectives of the One Health Initiative. • Review how the animals and the environment that human contact can affect their health and vice versa. • Discuss the human health risks related to contact with animals while traveling including: Direct contact with wildlife and wildlife souvenirs; Direct contact with companion animals; and Contact with high risk environments. • Learn how illnesses in animals can be a sentinel for disease in humans. <p>PL3.3 Travelling Humans and Travelling Animals: Health Risks from an Animal Perspective Corrie C. Brown, United States of America</p> <ul style="list-style-type: none"> • Review the connections between human, animal and environmental health with a focus on diseases from an animal perspective: reverse zoonoses due to ecotourism. • Describe pre-travel and post-travel evaluation of pets. • Review diseases that travelling pets can import home and spread to the human community. 	Auditorium, Level 1
10.30-11.15	Morning Break	Exhibition Level 1



Time	Program	Location
Wednesday, 22 May 2013, continued		
LBSY 11.15-12.45	<p>Late Breaker Symposium Changing Viral Infections in Europe and Africa (Emerging Viral Pathogens) <i>Chairs:</i> Garth Brink, South Africa Thomas Löscher, Germany</p> <p>LB1.1 <i>Novel Respiratory Pathogens</i> Ron Fouchier, The Netherlands</p> <p>LB1.2 <i>Medically Important Arboviruses in Europe</i> Natalie Cleton, The Netherlands</p> <p>LB1.3 <i>Haemorrhagic Fever in Africa</i> Daniel Bausch, United States of America</p>	Auditorium, Level 1
SY11 11.15-12.45	<p>Symposium 11 Expatriate Health Issues: Preparation and Living Abroad <i>Chairs:</i> Prativa Pandey, Nepal Frank von Sonnenburg, Germany</p> <p>SY11.1 <i>Mental Health in Expats</i> Sarah Borwein, Hong Kong</p> <ul style="list-style-type: none"> • Review epidemiology of mental health problems in expats. • Review interventions that can be applied before or during travel to try to minimize mental health problems. <p>SY11.2 <i>Health Problems and Preparing</i> Poh Lian Lim, Singapore</p> <ul style="list-style-type: none"> • Review health problems that are most common in expats and how they vary by type of expat. • Review interventions that are effective. <p>SY11.3 <i>Family Cycle Abroad</i> Michael E. Jones, United Kingdom</p> <ul style="list-style-type: none"> • Review practical challenges of dealing with health, social, educational, political, emergency, and other issues while living abroad. 	Brussels, Level 0 Room 0.4



Time	Program	Location
Wednesday, 22 May 2013, continued		
WS13 11.15-12.45	Workshop 13 Sex Tourism: What Travel Medicine Practitioners Need to Know Irmgard Bauer , Australia Alberto Matteelli , Italy <ul style="list-style-type: none"> • Describe the range of activities that fall within the definition of sexual tourism. • Describe origin of and trends in sexual tourism and regional variations. 	Paris, Level 0 Room 0.5
WS14 11.15-12.45	Workshop 14 Brazil and High Altitude Destinations in South America (Destination) Jesse Alves , Brazil Cecilia Perret , Chile <ul style="list-style-type: none"> • Describe characteristics and risks of common destinations in Brazil and Latin America, including high altitude destinations. • Describe characteristics of locations for the World Cup and Summer Olympics. 	Rome, Level 0 Room 0.8
FC7 11.15-12.45	Free Communication 7 Airlines, Altitude and Study Methods <i>Chairs:</i> Yves Van Laethem , Belgium Christopher Van Tilburg , United States of America	Athens, Level 0 Room 0.9
11.15-11.30	FC7.1 <i>In-flight Medical Incidents, Deaths and Flight Diversions of South African Airways Flights from 2009 till 2011</i> Salim Parker , South Africa	
11.30-11.45	FC7.2 <i>Incidence of Serious Altitude Sickness in Travellers who Consulted a Pre-travel Clinic</i> Mieke Croughs , The Netherlands	
11.45-12.00	FC7.3 <i>The Diagnosis of Juvenile Acute Mountain Sickness (AMS)</i> Tadashi Shinozuka , Japan	



Time	Program	Location
Wednesday, 22 May 2013, continued		
12.00-12.15	FC7.4 <i>The Role of Travellers from South East Asia on Dengue Activity in Singapore</i> Eduardo Massad , Brazil	
12.15-12.30	FC7.5 <i>Analyzing GeoSentinel Surveillance Data: A Comparison of Methods to Explore Acute Gastrointestinal Illness among International Travellers</i> Katherine E. Mues , United States of America	
12.30-12.45	FC7.6 <i>Pilot Randomised Controlled Trial to Testing Facemasks Effectiveness in Preventing Influenza-like Illness Transmission among Hajj Pilgrims</i> Ohsamah Barasheed , Australia	
12.45-14.45	Lunch Break	Exhibition, Level 1
13.15-14.30	ISTM GeoSentinel/EuroTravNet/CanTravNet Network Member Meeting • Open to all	Rome, Level 0 Room 0.8





Time	Program	Location
Wednesday, 22 May 2013, continued		
SY12 14.45-16.15	<p>Symposium 12 What Is the Diagnosis? Tests in Travellers <i>Chairs:</i> Martin Haditsch, Austria and Germany Mary-Louise Scully, United States of America</p> <p>SY12.1 <i>Use of IGRAs in Travellers and Immigrants</i> Kevin Schwartzman, Canada</p> <ul style="list-style-type: none"> • Describe the principles and limitations of interferon-gamma release assays for the diagnosis of (latent) tuberculosis. • Interpret the findings of Mantoux testing and IGRA in returning travellers and immigrants. • Determine when to use Mantoux testing or IGRA in returning travellers and immigrants for screening of latent TB. <p>SY12.2 <i>Usefulness of Molecular Diagnosis in PCR Stools</i> Lisette van Lieshout, The Netherlands</p> <ul style="list-style-type: none"> • Discussion on the limitations of microscopy for diagnosis of parasitic diseases has a limited sensitivity (microsporidium, strongyloides), specificity (E. histolytica vs E. dispar). • Presentation of study results demonstrating the usefulness of PCR for diagnosis of parasitic diseases. <p>SY12.3 <i>Pitfalls and Practice with Rapid Diagnostic Tests</i> Emmanuel Bottieau, Belgium</p> <ul style="list-style-type: none"> • Short introduction about diagnostic tests and sensitivity, specificity and likelihood ratio's. • Presentation of study results demonstrating usefulness of RDT for malaria, dengue fever, leptospirosis, others. 	Auditorium, Level 1





Time	Program	Location
Wednesday, 22 May 2013, continued		
LBS 14.45-16.15	<p>Late Breaker Special Session Updates on JE Vaccines and Ongoing Outbreak of Sarcocystosis <i>Chairs:</i> David Hamer, United States of America Gerard JB Sonder, The Netherlands</p> <p>LBS1.1 Japanese Encephalitis Marc Fischer, United States of America</p> <p>LBS1.2 Japanese Encephalitis Vaccine Katrin Dubischar-Kastner, Austria</p> <p>LBS1.3 Sarcosystosis Douglas Esposito, United States of America</p> <p>LBS1.4 A Family Cluster of Sarcocystosis in Travelers returning from Tioman Island, Malaysia, including a Histologically Proven Case with Results of Treatment Loïc Epelboin, France</p> <p>LBS1.5 Cluster of Acute Muscular Sarcocystis-like Infection in 12 Travelers Returning from Peninsular Malaysia, 2012, Bordeaux, France Duc Nguyen, France</p>	Brussels, Level 0 Room 0.4
WS15 14.45-16.15	<p>Workshop 15 Pox, Pustules and Lumps: Skin Lesions in Returned Travellers Eric Caumes, France Jay Keystone, Canada</p> <ul style="list-style-type: none"> • In a case based format review the most common skin lesions acquired during travel and provide a practical approach to diagnosis and management. 	Paris, Level 0 Room 0.5





Time	Program	Location
Wednesday, 22 May 2013, continued		
WS16 14.45-16.15	Workshop 16 On the Road with HIV Francesco Castelli , Italy Marc Mendelson , South Africa <ul style="list-style-type: none"> • 3-4 case studies will be discussed. Susceptibility for specific infections will be debated. Examples of possible interactions between antimalarials and antiretroviral therapies will be given. Useful websites addresses to predict drug-drug interactions will be provided. 	Rome, Level 0 Room 0.8
WS17 14.45-16.15	Workshop 17 Babes on the Road: Pregnant and Infant Travellers I. Dale Carroll , United States of America Catherine Riley , United Kingdom <ul style="list-style-type: none"> • In a case based format review a practical approach to providing pre-travel advice for commonly encountered issues of prevention, prophylaxis and treatment specific to pregnant and infant travellers. 	Athens, Level 0 Room 0.9
16.15-17.15	Afternoon Break and Poster Session	Exhibition, Level 1
17.15-18.45	ISTM Membership Assembly	Auditorium, Level 1
18.45-19.30	Cocktail Reception for ISTM Members	Auditorium, Level 1





Time	Program	Location
Thursday, 23 May 2013		
COD4 08.00-08.45	Case of the Day 4 Philippe Parola , France	Paris, Level 0 Room 0.5
SY13 09.00-10.30	<p>Symposium 13</p> <p>Fit for Travel: Trip Prep for Older Travellers</p> <p>Chairs: Eric Caumes, France Mary-Louise Scully, United States of America</p> <p>SY13.1 Polypharmacy and Travel Medicines Caroline Zeind, United States of America</p> <ul style="list-style-type: none"> • Review of changed pharmacokinetics and pharmacodynamics of frequently used drugs in elderly. • Judge frequently used drugs in elderly on possible side effects due to anticholinergic activity. • Describe how to prevent potential severe adverse events of diuretics, NSAID, ACE-inhibitors and statins during dehydration. • Apply tools to tackle polypharmacy in elderly travelers. <p>SY13.2 Evaluation of Fitness for Travel Jan Hindrik Ravesloot, The Netherlands</p> <ul style="list-style-type: none"> • Give examples of age-related physiological changes and explain their clinical significance. • Name tests for physical activity, fitness and longevity in elderly. • Assess fitness for travel in elderly traveller. <p>SY13.3 Immunosenescence and Vaccines Brian Ward, Canada</p> <ul style="list-style-type: none"> • List changes in innate and adaptive immunity during old age. • Give examples of increased infectious risks due to immunosenescence. • Discuss consequences of immunosenescence for secondary immune response to travel vaccines. • Discuss consequences of immunosenescence for primary immune response to travel vaccines. 	Auditorium, Level 1



Time	Program	Location
Thursday, 23 May 2013, continued		
WS18 09.00-10.30	Workshop 18 Leish Basics: Diagnosis and Treatment of Leishmaniasis Johannes Blum , Switzerland Andrea K. Boggild , Canada <ul style="list-style-type: none"> • 3 case studies discussed will provide a review of diagnostic tests available and their indication as well as a review of treatments available for the most frequent Leish species. 	Brussels, Level 0 Room 0.4
WS19 09.00-10.30	Workshop 19 The Humanitarian Aid Worker: Ethics and Preparation Ted Lankester , United Kingdom Christopher Van Tilburg , United States of America <ul style="list-style-type: none"> • Review specific risks and situations related to the provision of humanitarian care. • Explain how to prepare for these specific risk and situations such as: exposure to the specific environment, such as in a natural disaster or conflict; working long hours under adverse or extreme conditions; damaged or absent infrastructure; reduced levels of security. • Discuss how to appraise stress, ethical, and moral challenges related to the event and the resource capacities of the situation. 	Paris, Level 0 Room 0.5
10.30-10.45	Morning Break	Auditorium Foyer, Level 1





Time	Program	Location
Thursday, 23 May 2013, continued		
PL4 10.45-12.15	<p>Plenary 4 Mass Gatherings: Local and Global Consequences <i>Chairs:</i> Fiona Genasi, United Kingdom David R. Shlim, United States of America</p> <p>PL4.1 <i>Non-communicable Health Risks During Mass Gatherings</i> Robert Steffen, Switzerland</p> <ul style="list-style-type: none"> • Describe the leading causes of mortality and morbidity during mass gatherings; human stampedes and heat-related illnesses are the leading causes of mortality; warm weather, extreme weather conditions and emotional stress of morbidity. • Recognize traveller's characteristics associated with increased risk of illness or injury. • Women, very young and very old are more vulnerable during mass gatherings. • Formulate health advice to reduce illness and injury; effective strategies to prevent heat stroke, cardiovascular accidents. <p>PL4.2 <i>Maha Kumbh Mela, Largest Public Gathering in the World</i> Satchit Balsari, United States of America</p> <ul style="list-style-type: none"> • Discuss the public health risks and how these health risks were met. • Review implications for global health security. • New aspects of surveillance that have been put in place for 2012 and as part of our legacy will be covered. <p>PL4.3 <i>Lessons Learned from the 2012 Summer Olympics: London's Preparations for the Global Visitor</i> Brian McCloskey, United Kingdom</p> <ul style="list-style-type: none"> • Lessons learned for the global traveller: exchange of experience between organisers and hosts of mass gathering provide the opportunity to formulate guidelines generally applicable in all countries of the world. • Discussion on the international collaboration with WHO and ECDC and the role of the WHO Collaborating Centre here. 	Auditorium, Level 1
12.15-12.45	Closing Ceremony	Auditorium, Level 1

ISTM

CTH

The **International Society of Travel Medicine Certificate of Knowledge** is a symbol of achievement in the field of travel medicine. As the first international certificate devoted solely to travel health, it recognizes professionals who have demonstrated expertise in the unique body of knowledge associated with the practice of travel medicine.

Wednesday, 7 May 2014
in Ho Chi Minh City, Vietnam

In conjunction with the
10th Asia Pacific Travel Health Conference

- and -

Sunday, 3 August 2014
in Jackson Hole, Wyoming USA

in conjunction with the
6th Regional Conference of the International Society of Travel Medicine
and the
2014 Summer Conference of the Wilderness Medical Society

To register for the Exam, or for more information, go to www.ISTM.org.





Posters

Airline or Maritime Medicine

PO01.01

Retrospective Study of Deaths of Air Travelers Attended at Chhatrapati Shivaji International Airport, Mumbai

A.D. More¹

¹Mumbai International Airport Pvt Ltd, Medical Services, Mumbai, India

PO01.02

Medical Problems Encountered during Two Circumnavigations by Semester at Sea

P.D. Sloane¹, A. Herweck², A. Malley², S. Zimmerman³

¹University of North Carolina - Chapel Hill, Family Medicine, Chapel Hill, United States, ²University of San Diego, San Diego, United States, ³University of North Carolina - Chapel Hill, Cecil G Sheps Center for Health Services Research, Chapel Hill, United States

PO01.03

Plasmodium ovale in Seafarers on Greek Merchant Ships Calling at African Ports

E. Vassalou¹, C.M. Vassalos¹, G. Spanakos¹, N. Vakalis¹

¹National School of Public Health, Department of Parasitology and Tropical Diseases, Athens, Greece

Altitude, Diving or Environmental Exposures

PO02.01

Vibrio and Stenotrophomonas in the Caribbean Sea: A Potential Source of Infections in Divers and Snorkelers

R. Naraine¹, K. Farmer¹, S. Kotelnikova¹

¹St. George's University, Microbiology, St. George, Grenada

PO02.02

Drug Resistance and Frequencies of Resistant E.coli and E.fecalis in Oceanic Tropical Waters of Grenada

S. Kotelnikova¹, V. Amadi²

¹St. George's University, Microbiology, St. George's, Grenada, ²St. George's University, St George's, Grenada

PO02.03

Potentially Dangerous Consequences of a Bad-Managed Pre-travel Consultation

A. Rossanese¹, F. Gobbi¹

¹'Sacro Cuore-Don Calabria' Hospital, Centre for Tropical Diseases, Negrar, Verona, Italy

PO02.04

Acute Mountain Sickness Complicated by High-Altitude Pulmonary Edema and High-Altitude Cerebral Edema in a 35-Year Old Hong Kong Traveler Visiting Lake Titicaca, Peru

C.K.B. Wong¹

¹Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong

Enteric Infections

PO03.01

Strongyloides Stercoralis as a Cause of Enteric Infection Is Underestimated in Slovenia and in Balkan Region

M. Skvarc¹, P. Rogina²

¹Faculty of Medicine Ljubljana, Institute of Microbiology and Immunology, Ljubljana, Slovenia, ²General Hospital Novo Mesto, Novo Mesto, Slovenia

PO03.02

Safety and Efficacy of a Travelers' Diarrhea Patch Vaccine System Containing Heat-labile Toxin from Enterotoxigenic Escherichia coli (ETEC) in Travelers to Asia: A Randomized, Double-blind, Placebo-Controlled Phase 2 Trial

J.P. Cramer^{1,2}, R.H. Behrens³, G.D. Burchard^{1,2}, T. Jelinek⁴, U. Schwarz⁴, R. Prabhugaunker⁵, S. Chatterjee⁶, S.

Dewasthaly⁷, K. Westritschnig¹, R. Steffen⁸

¹University Medical Center Hamburg-Eppendorf (UKE), Department of Tropical Medicine, Hamburg, Germany,

²Bernhard Nocht Institute for Tropical Medicine, Clinical Research Department, Hamburg, Germany, ³Hospital for

Tropical Diseases, Travel Medicine, London, United Kingdom, ⁴Berliner Centrum Reise & Tropenmedizin, Berlin,

Germany, ⁵Prabhugaunker's Clinic, Goa, India, ⁶Wellesley Medicentre, Kolkata, India, ⁷Intercell AG., Vienna,

Austria, ⁸University of Zurich, Institute of Social and Preventive Medicine, Division of Epidemiology and Prevention of Communicable Diseases, Zurich, Switzerland



Posters, continued

PO03.03

Characterization of Enterotoxigenic *Escherichia Coli* Strains in Patients with Acute Diarrhea in Mexico, Guatemala, India and United States

Z.-D. Jiang¹, V. Kharat¹, J.A. Boom², L.C. Sahni², H.L. Dupont¹
¹University of Texas, Houston, United States, ²Texas Children's Hospital, Houston, United States

PO03.04

Rapid Cessation of Acute Diarrhea in Pediatric Patients Using a Novel Plant Extract: Results of a Randomized, Cross-over Study

A.S. Dover¹
¹LiveLeaf Bioscience, Inc., San Carlos, United States

PO03.05

Traveler's Diarrhea among Foreign Travelers in Southeast Asia

C. Kittittrakul¹, W. Piyaphanee¹, W. Tangkanakul², S. Lawpoolsri³
¹Mahidol University, Department of Clinical Tropical Medicine, Bangkok, Thailand, ²Ministry of Public Health, Department of Disease Control, Bangkok, Thailand, ³Mahidol University, Department of Tropical Hygiene, Bangkok, Thailand

PO03.06

Intestinal Parasitism in Business Travellers from 2002 to 2012: Review of 17536 Fecal Specimens Analysis in a French Travel Clinic Laboratory

M. Plisson-Sauné¹, X. Chanudet¹, D. Martin¹, I. Tawa¹, P. Piot¹, N. Poulbère¹, M. Carsault¹, F. Tournois¹, O. Marendowski¹, L. Perthuisot¹
¹CMETE, Paris, France

PO03.07

The Importance of Norovirus as a Cause of Travelers' Diarrhea Is Ill Defined and Underestimated

J. Verstraeten¹
¹P95, Pharmacovigilance and Epidemiology Services, Leuven, Belgium

PO03.08

Case Report of an Outbreak of norovirus on a Cruise Ship

H. Visser¹
¹Public Health Service Rotterdam-Rijnmond, Infectious Disease Control, Rotterdam, Netherlands

PO03.09

A Description of Enteric Fever Cases in Auckland, New Zealand from 2005 to 2010

R.J. Lane¹, S. Mc Bride¹, D. Holland¹, S. Perera², T. Jelleyman³, K. Read⁴, R.J.H. Ingram⁵
¹Middlemore Hospital, Infectious Diseases, Auckland, New Zealand, ²Auckland Regional Public Health Service, Auckland, New Zealand, ³Waikare Hospital, Auckland, New Zealand, ⁴North Shore Hospital, Auckland, New Zealand, ⁵Auckland City Hospital, Infectious Diseases, Auckland, New Zealand

PO03.10

Amebic Liver Abscess: Epidemiological, Clinical Data and Outcome in a Series of 53 Travelers

C. Rapp¹, C. Valentin², C. Verret³, J. Margery⁴, F. Simon⁵, T. Carmoi⁶, C. Ficko², O. Aoun²
¹Begin Military Hospital, Infectious and Tropical Diseases, Saint-Mandé, France, ²Begin Military Hospital, Saint-Mandé, France, ³CESPA, Paris, France, ⁴HIA Percy, Clamart, France, ⁵HIA Laveran, Marseille, France, ⁶HIA Val de Grace, Paris, France

Infectious Diseases: Epidemiology, Diagnosis, Treatment

PO04.01

Case report: Acute Military Tuberculosis Aeromedical Evacuation with a Positive Pressure Aircraft Transit Isolator

H. Raffin^{1,2}
¹Medic'Air International, Bagnolet, France, ²SAMU de Paris, DAR Necker Enfants-Malades, Paris, France

PO04.02

Reasons for Outpatient Visits by Foreign Travellers to an Urban Hospital in Tokyo

N. Matsuda¹, T. Naito¹, Y. Uehara¹, H. Isonuma¹, T. Hisacka¹
¹Juntendo University, General Medicine, Bunkyo-ku, Japan



Posters, continued

PO04.03

Prevalence of Placental Toxoplasmosis in the Greater Accra Region of Ghana

K.D. Kwofie^{1,2}, A. Ghansah¹, J.H.N. Osei¹, S. Obed³, E.H. Frimpong¹, T. Suzuki⁴, N. Ohta⁴, I. Ayi¹
¹*Noguchi Memorial Institute for Medical Research, Parasitology Department, Accra, Ghana,* ²*Kwame Nkrumah University of Science and Technology, Clinical Microbiology, SMS, Kumasi, Ghana,* ³*Korle-Bu Teaching Hospital, Obstetrics and Gynaecology Department, Korle-Bu, Accra, Ghana,* ⁴*Tokyo Medical and Dental University, Department of Environmental Parasitology, Tokyo, Japan*

PO04.04

Possible and Proven Mixed Infection of Schistosomiasis and Strongyloidosis: A Single Centre Retrospective Analysis

P. Soentjens^{1,2}, A. Aerssens², J. Verschueren¹, D. Van den Bossche³, M. Van Esbroeck¹
¹*Institute of Tropical Medicine, Department of Clinical Sciences, Antwerp, Belgium,* ²*Military Hospital Queen Astrid, Polyclinic Department, Brussels, Belgium,* ³*Military Hospital Queen Astrid, Lab Department, Brussels, Belgium*

PO04.05

Schistosomiasis Serology in Travellers and Immigrants Returning to Edinburgh, UK: A Retrospective Preliminary Analysis

S. Durkin¹, C. Alexander², K.O. Helgason³, M.E. Jones⁴
¹*Edinburgh University, Edinburgh, United Kingdom,* ²*Stobhill Hospital, Scottish Parasitology Laboratory, Glasgow, United Kingdom,* ³*Royal Infirmary of Edinburgh, Microbiology, Edinburgh, United Kingdom,* ⁴*Western General Hospital, Regional Infectious Diseases Unit, Edinburgh, United Kingdom*

PO04.06

Mapping of Filaria Infection in Domestic Cats Living in Brugian Filariasis-endemic Areas Using a Real Time PCR with HRM Analysis

S. Wongkamchai¹, H. Nochot¹, S. Foongladda², P. Dekumyoy³, S. Loymek⁴, J.J.J. Boitaino¹, W. Choochote⁵
¹*Mahidol University, Parasitology, Faculty of Medicine Siriraj Hospital, Bangkok, Thailand,* ²*Mahidol University, Microbiology, Faculty of Medicine Siriraj Hospital, Bangkok, Thailand,* ³*Mahidol University, Helminthology, Faculty of Tropical Medicine, Bangkok, Thailand,* ⁴*Filaria Project, Phikulthong Royal Development Study Center, Narathiwat, Thailand,* ⁵*Chiangmai University, Parasitology Faculty of Medicine, Chiangmai, Thailand*

PO04.07

Candida Species of Bloodstream Isolates and Antifungal Susceptibility of Candida in the Biggest Tertiary Hospital in Thailand

S. Foongladda¹, P. Petlum¹, D. Boonlert¹, N. Mongkol¹
¹*Mahidol University, Department of Microbiology, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand*

PO04.08

Evaluation of the Diagnosis of Travel-related Acute Schistosomiasis Syndrome by Serum PCR: Expertise from a Single Centre

L. Chops^{1,2}, P. Soentjens^{1,2}, J. Clerinx¹, M. Van Esbroeck¹
¹*Institute of Tropical Medicine, Antwerp, Belgium,* ²*Military Hospital Queen Astrid, Brussel, Belgium*

PO04.09

What Infectious Diseases Are Mostly Reported Following Travelling Abroad? What Types of Travelers Are Affected? Norway, 2011

B. Guzman Herrador¹, T. Bruun¹, L. Vold¹, H. Blystad¹
¹*Norwegian Institute of Public Health, Oslo, Norway*

PO04.10

Imported Human Rabies Cases Worldwide, 1990-2012

P. Carrara¹, P. Parola¹, P. Brouqui¹, P. Gautret¹
¹*IHU Méditerranée Infection, Marseille, France*

PO04.11

Recombinant Nonstructural 1 (NS1) Protein of Dengue Virus for Diagnosis of Dengue Virus Infection

U. Kositanont¹, P. Panyarakkit¹, S. Anantaprecha²
¹*Faculty of Medicine Siriraj Hospital, Mahidol University, Department of Microbiology, Bangkok, Thailand,* ²*National Institute of Health, Ministry of Public Health, Department of Medical Sciences, Nonthaburi, Thailand*

PO04.12

Severe Malaria in Canada: Management through the Canadian Malaria Network

A.E. McCarthy¹, J. Geduld², C. Prematunga³, on behalf of the Canada Malaria Network
¹*University of Ottawa and the Ottawa Hospital, Dept of Medicine, Ottawa, Canada,* ²*Public Health Agency of Canada, Ottawa, Canada,* ³*University of Ottawa, Ottawa, Canada*



Posters, continued

PO04.13

One Case of Cerebral Falciparum Malaria Onset as Thrombocytopenia in a Returning Traveller from China

X.-Y. Wang¹, S.-L. Yu¹, Y.-X. Huang¹, W.-H. Zhang¹

¹Huashan Hospital, Fudan University, Department of Infectious Diseases, Shanghai, China

Long-stay Travellers, including expatriates

PO05.01

A Travel Clinic as a Company Hospital

K. Miyagi¹, M. Nonaka¹, M. Osabe¹

¹Nagasaki Shipyard & Machinery Works Hospital, Mitsubishi Heavy Industries, Ltd., Department of Internal Medicine, Nagasaki, Japan

PO05.02

The Medical Evacuation Response Plan (MERP) - a Tool for Companies to Perform Duty of Care for their Travelers and Expatriates While Working Abroad

S. Esser¹

¹International SOS, Central Europe Medical Department, Neu-Isenburg, Germany

PO05.03

High Proportion of Unprotected Casual Sexual Contacts among Dutch Long-Term Travellers to Sub-Tropical Countries, Though No Seroconversions for HIV or Syphilis

J. Whelan^{1,2}, S. Belderok^{1,2}, G. Sonder^{1,2}, A. van den Hoek^{1,2}

¹Public Health Service (GGD), Department of Infectious Diseases, Amsterdam, Netherlands, ²Academic Medical Center/ University of Amsterdam, Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, Amsterdam, Netherlands

PO05.04

Changes in Expatriate Psychosocial Well-being during Overseas Assignment

K.L. Gamble¹, D. Westwood², J. Gamble², N. Gamble²

¹Missionary Health Institute, Canada, Canada, ²Missionary Health Institute, Toronto, Canada

Migrants and Refugees

PO06.01

Developing a Tool to Help Newcomers Refugees

S. Gagnon¹, M. Chamula², I. Pirija²

¹CSSS de la Vieille-Capitale, Clinique Santé des Immigrants-Réfugiés, Québec, Canada, ²Université Laval, Etudiante, Québec, Canada

PO06.02

Health of Migrant and Travel Medicine: A New Approach for Visiting Friends and Relatives

L. Pecoraro¹, T. D'Arca¹, I. Uccella¹, R. Testa¹, G. Costanzo¹, C. Mirisola¹

¹National Institute for Health, Migration and Poverty, Rome, Italy

PO06.03

Overseas Tuberculosis (TB) Screening in Peruvian Immigrants to United States

H.R. Siu^{1,2}, N. Lari¹, J. Echevarria^{2,3}

¹British American Hospital / Clinica Anglo Americana, Travel Medicine, Lima, Peru, ²Universidad Peruana Cayetano Heredia, Instituto de Medicina Tropical Alexander von Humboldt, Lima, Peru, ³British American Hospital / Clinica Anglo Americana, Infectious Diseases, Lima, Peru

PO06.04

Perception of Emotional and Behavioral Problems among Refugee Children Living in Canada

S. Gagnon¹, M.-C. Duquette¹, C. Rousseau¹, P.G. Tremblay¹

¹Institut National de Santé Publique Du Québec, Québec, Canada, ²Centre Hospitalier Universitaire de Québec, Québec, Canada, ³Sick Children Hospital, Psychiatry, Montreal, Canada

PO06.05

Cases of Community-acquired MRSA (CA-MRSA) among Immigrants Seen in NYC Community Health Centers

N. Piper Jenks¹, J.N. Tobin^{1,2}, R.G. Kost², S. Balachandra², O. Okpukpara¹, C. Khalida¹, A. Tsang¹, B. Rumala², C. Coffran², M. Pastagia², T. Evering², P. Holt², H. de Lencastre², A. Tomasz², M. Pardo², B. Collier²

¹Clinical Directors Network (CDN) c/o Hudson River Community Health, Internal Medicine, Peekskill, United States, ²The Rockefeller University for Clinical and Translational Science (CCTS), New York, United States



Posters, continued

PO06.06

Cases of Shingles (Herpes Zoster) among Young Healthy Migrants, during a Period of Increasing Varicella Vaccine Coverage

N. Piper Jenks¹, J. Koren¹, C. Kananen¹, J. Yao¹

¹Hudson River Community Health, Internal Medicine, Peekskill, United States

PO06.07

Taeniasis among Refugees on the Thailand-Burma Border

E.J. McCleery¹, P. Patchanee², S. Chailangkarn², P. Pongsojawijit², S. Tiwananthagorn², P. Jongchansitoo³, A. Dantrakool⁴, N. Morakote⁵, H. Phyu⁵, S. O'Neal¹

¹Oregon Health & Science University, Public Health & Preventive Medicine, Portland, United States, ²Chiang Mai University, Faculty of Veterinary Medicine, Chiang Mai, Thailand, ³Division of Livestock Development, Mae Hong Son, Thailand, ⁴Chiang Mai University, Faculty of Medicine, Department of Parasitology, Chiang Mai, Thailand, ⁵International Rescue Committee, Mae Hong Son, Thailand

PO06.08

Dramatical Fall in Comoros-acquired Malaria in Marseille, France, 2001-2011

H. Savini¹, C. Martel¹, A. Ali Mohamed¹, P. Gautret¹, P. Minodier², R. Piarroux³, P. Parola⁴, F. Simon¹

¹Military Teaching Hospital of Laveran, Unit of Infectious and Tropical Diseases, Marseille, France, ²Hôpital Nord, Assistance-Publique Hôpitaux de Marseille, Pediatric Emergency, Marseille, France, ³Assistance-Publique Hôpitaux de Marseille, Department of Parasitology and Mycology, Marseille, France, ⁴EuroTravNet Coordinating Center, University Hospital Institute for Infectious and Tropical Diseases, Aix-Marseille University and Assistance-Publique Hôpitaux de Marseille, Marseille, France

PO06.09

Description of Discrete Typing Units of *Trypanosoma cruzi* in Migrant Bolivian Patients with Chagas Disease: The Strains Remain the Same

J.A. Perez-Molina¹, C. Poveda², A. Martínez-Pérez¹, F. Guhl², F. Norman¹, M. Fresno³, R. Lopez-Velez¹, N. Gironés²

¹Hospital Ramon y Cajal, Tropical Medicine and Clinical Parasitology, Infectious Diseases Department, Madrid, Spain, ²Universidad de los Andes, Centro de Investigaciones en Microbiología y Parasitología Tropical, CIMPAT, Bogotá, Colombia, ³CSIC-UAM, Centro de Biología Molecular Severo Ochoa, Madrid, Spain

Non-infectious Disease Travel Risks (e.g., pulmonary emboli, jet lag)

PO07.01

Resurgence of Bed Bugs in Thailand and Their Insecticide Resistance: A Pest Control Challenge

A. Tawatsin¹, U. Thavara¹, J. Chompoonsri¹, P. Bhakdeenuan¹, Y. Phusup¹, S. Sangkitporn¹, P. Siriyasatien²

¹National Institute of Health, Department of Medical Sciences, Nonthaburi, Thailand, ²Department of Parasitology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

Occupational and Military Medicine

PO08.01

Development of In-house Travel Medicine Services for a Large Multinational Corporation

A. Trauscht¹, T. Wright²

¹Advocate Health Care, Occupational Health, Lake Zurich, United States, ²W. W. Grainger, Inc, Health Services, Lake Forest, United States

PO08.02

First Approach on Global Occupational Health and Travel Medicine Care Reporting Inside a Multinational Company

S. Esser¹

¹International SOS, Central Europe Medical Department, Neu-Isenburg, Germany

PO08.03

Paederus Dermatitis: Also an Offshore Problem? - Cases from Equatorial Guinea

M. Feltemig¹, J. Teletea², B. Dees³

¹International SOS, MS-Middle East, Nigeria and Equatorial Guinea, Dubai, United Arab Emirates, ²International SOS, MS-Nigeria, Equatorial Guinea, Bata, Equatorial Guinea, ³International SOS, MS-EECA and OH, Dubai, United Arab Emirates



Posters, continued

PO08.04

Body System Involved in Case Presentations on Offshore Installations - Is There a Difference between West Africa and Middle East? - A Preliminary Report

S. Ibrahim¹, A. Nosa², B. Dees³, M. Fellemid⁴

¹International SOS, Middle East, Dubai, United Arab Emirates, ²International SOS, Nigeria, Port Harcourt, Nigeria,

³International SOS, EECA and OH, Dubai, United Arab Emirates, ⁴International SOS, Middle East, Nigeria and Equatorial Guinea, Dubai, United Arab Emirates

PO08.05

Extreme Long-Term Exposure to Fresh Water and Soil in the DRC: Active Screening Results for the Detection of Acute Schistosomiasis and Strongyloidosis from two BE Military Cohorts.

P. Soentjens^{1,2}, A. Aerssens¹, B. Damanet¹, P. Andries¹, A. Wauters¹, L. Cnops², M. Van Esbroeck²

¹Military Hospital Queen Astrid, Polyclinic Department, Brussels, Belgium, ²Institute of Tropical Medicine, Department of Clinical Sciences, Antwerp, Belgium

PO08.06

Initial Neutralising Antibody Response to 3 or 4 Rabies Intradermal Pre-exposure Vaccination: Is There a Difference? A Single-Center Retrospective Analysis

P. Soentjens^{1,2}, B. Damanet¹, P. Andries¹, B. Henrion¹, C. Arnould¹, A. Aerssens¹

¹Military Hospital Queen Astrid, Polyclinic Department, Brussels, Belgium, ²Institute of Tropical Medicine, Department of Clinical Sciences, Antwerp, Belgium

Pre-travel Advice and Approaches; Risk assessment/communication

PO09.01

A Pilot Study on Testing the Effect of HIV Information

G. Hasle¹, L. Heier², G. Bjune³

¹Reiseklinikken - Oslo Travel clinic, Oslo, Norway, ²University of Oslo, Dept. of Biology, Oslo, Norway, ³University of Oslo, Institute of Health and Society, Faculty of Medicine, Oslo, Norway

PO9.02

Evaluating the Effectiveness of the Pre-travel Visit

J. Richards¹, N. Masunaga²

¹Vaden Health Center, Stanford University, Menlo Park, United States, ²Vaden Health Center, Stanford University, Stanford, United States

PO09.03

Which Anti-Malarial? Analysing the Complexities and Variables Involved in Making Safe and Effective Recommendations to Travellers

A. Willcox¹, H. Chera¹, G. Hewitt¹, A. Halliday¹

¹Health Team Ltd., Birmingham, United Kingdom

PO09.04

Travel Health Services Experience from a New Travel Clinic in Doha, Al Ahli Hospital, Doha, Qatar

A. Baxarawi¹

¹Al Ahli Hospital, Doha, Qatar

PO09.05

Travel Related Medications and their Interaction with Chronic Therapy: Highly Frequent and Easily Overlooked during Pre-travel Consultation

S. Stienlauf^{1,2,3}, B. Streltsin^{3,4}, E. Kopel^{1,2}, E. Meltzer^{1,2,3}, E. Leshem^{1,2,3}, D. Kurnik^{2,3}, G. Segal^{2,3}, E. Schwartz^{1,2,3}

¹The Sheba Medical Ctr, The Travel Clinic & the Center for Tropical Medicine, Tel Hashomer, Israel, ²The Sheba Medical Ctr, Departments of Internal Medicine, Tel Hashomer, Israel, ³Tel-Aviv University, Sackler School of Medicine, Tel-Aviv, Israel, ⁴The Sheba Medical Ctr, The Arrow Project, Tel Hashomer, Israel

PO09.06

Communicating Flu Prevention Messages to US-Mexico Land Border Crossers: Lessons Learned

S. Erskine¹, K. Holton¹, K. Carera², A. Rodriguez Lainz¹, D. Borntrager¹, L. Lange², R. Myers¹, T. Schwartz-Kitchens¹, S. Hale²

¹Centers for Disease Control and Prevention, Division of Global Migration and Quarantine, Atlanta, United States,

²Oak Ridge Associate Universities/Oak Ridge Institute for Science and Education, Oak Ridge, United States



Posters, continued

PO09.07

Knowledge, Attitudes and Practices Evaluation About Travel Medicine Counseling in Italian Customers of Pharmacies in Calabria, Italy

S. Neri¹, F. Foti²

¹Salus Pharmacy 'Dr. Neri Quintino', Reggio Calabria, Italy, ²La Feluca Travel Clinic, Reggio Calabria, Italy

PO09.08

Pre-travel Risk Discussion: How Many and Which Topics are Discussed in an Average Pre-travel Consultation?

M. Croughs^{1,2}, A. de Gouw¹

¹GGD Hart voor Brabant, Travel Clinic, 's-Hertogenbosch, Netherlands, ²Institute of Tropical Medicine, Department of Clinical Sciences, Antwerp, Belgium

PO09.09

HIV Post Exposure Prophylaxis Following Sexual Exposure: A Missed Opportunity for Intervention during the Pre-travel Consultation?

D. Brawley¹, A. Rea¹

¹Sandyford, Glasgow, United Kingdom

PO09.10

What Needs to Prepare for a Long Flight to Asia? - Lessons Learned from an Emergency Landed Case with Acute Exacerbation of Chronic Renal Failure

S. Otsu¹, S. Yamaji¹

¹Japanese Red Cross Wakayama Medical Center, Wakayama City, Japan

PO09.11

Pre-travel Consultations in a Travel Clinic: An Opportunity for Interprofessional Education

S. Seed¹, K. Sullivan¹, K. Dunican¹, L. Spooner¹, K. O'Connor², G. Abraham³

¹MCPHS University, Pharmacy Practice, Worcester, United States, ²Saint Vincent Hospital, Ambulatory Care Clinic, Worcester, United States, ³Saint Vincent Hospital, Medicine, Worcester, United States

PO09.12

Seroprevalence of Hepatitis A in Argentine Travelers and Cost-saving Analyses of Two Preventive Strategies

A. Macchi¹, C. Biscayart¹, V. Verdaguer¹, P. Elmassian¹, M.R. Tisi Bana², M.L. Strada¹, M. Dalbosco¹, D. Stambouliau¹

¹División Medicina del Viajero, Stambouliau Servicios de Salud, Buenos Aires, Argentina, ²Internal Medicine Department, Hospital Universitario Austral, Pilar, Argentina

PO09.13

A Report on Travel and Vaccination Patterns over a 5 Years Period from a Travel Clinic in Northern Italy

M. Migliorini¹, F. Marchioni¹, D. Berti¹, F. Tognon¹, S. Tardivo¹, F. Gobbi¹, A. Rossanese²

¹University of Verona, Dept. of Public Health, Verona, Italy, ²Sacro Cuore-Don Calabria Hospital, Centre for Tropical Diseases, Negrar, Verona, Italy

PO09.14

Can You Understand Me Now? Online Focus Group Testing of Travel Health Messages for Clear Communication

A.W. Lee¹, S. Erskine¹, C. Brown², B. Wilburn², K. Holton¹

¹Centers for Disease Control and Prevention, Travelers' Health Branch, Division of Global Migration and Quarantine, Atlanta, United States, ²Oak Ridge Associated Universities, Health Communication and Technical Training, Oak Ridge, United States

P9.15

You Want Me To Do What? A Qualitative Analysis of the Feasibility of Travel Health Recommendations

K. Holton¹, A.W. Lee¹, S. Erskine¹, C. Brown², B. Wilburn²

¹Centers for Disease Control and Prevention, Travelers' Health Branch, Atlanta, United States, ²Oak Ridge Associated Universities, Health Communication and Technical Training, Oak Ridge, United States

PO09.16

Travel Health: Perceptions and Practices of Travel Agents in London

E.L. Pine¹

¹RCPSPG, Glasgow, United Kingdom



Posters, continued

PO09.17

Promoting Diphtheria, Acellular Pertussis, Tetanus, Polio (DaPTP) Booster Vaccination instead of DiphtheriaTetanusPolio (DTP) Booster Vaccination to Travelers to Protect during and post Travel: A Retrospective Analysis in Dutch Travel Clinics

P.A. de Beer^{1,2}, H.A. Caris²

¹Medical Services for the Tropics, Maastricht, Netherlands, ²365-Center for Infection Prevention (CIP) and Travel Clinics, Utrecht, Netherlands

PO09.18

To Notify or Not To Notify: Agency Perspectives on the Development of Travel Health Notices

K.E. Spruit-McGoff¹, J. Geuld², D. Jermacane³, C.V. Lee¹, R. Henry¹, M. Crawley O'Sullivan¹, K. Holton¹, G. Brunette¹, C. Brown⁴

¹Centers for Disease Control and Prevention, Travelers' Health Branch, Atlanta, United States, ²Public Health Agency of Canada, Ottawa, Canada, ³National Travel Health Network and Centre, London, United Kingdom, ⁴Centers for Disease Control and Prevention, Atlanta, United States

PO09.19

Overview of 1749 Travelers Visiting the AMC Center of Travel Medicine from July 2011 to July 2012

R.W. Wielen¹, M.R. van der Schalie¹, C. Stijns¹, P.P.A.M. van Thiel¹, A. Goorhuis¹, M. van Vugt¹, M.P. Grobusch¹

¹Academic Medical Center/ University of Amsterdam, Center of Tropical and Travel Medicine, Department of Infectious Diseases, Division of Internal Medicine, Amsterdam, Netherlands

PO09.20

Travel Agents and Travel Health Promotion: A Study in the Local Health Authority Lucca

R. Banducci¹, G. Pierami¹, D.R. de Wet², A. Tomasi³, K. Farmer⁴

¹University of Pisa, Hygiene and Preventive Medicine, Pisa, Italy, ²University of Bologna, Department of Biomedical and Neuromotor Sciences, Bologna, Italy, ³AUSL 2 Lucca, Department of Prevention, Lucca, Italy, ⁴St. George's University, Microbiology, St. George, Grenada

PO09.21

The Emergency Department as a Venue for Pre-travel Prophylaxis and Advice

R. Partridge^{1,2}, L. Proano²

¹Warren Alpert Medical School of Brown University, Department of Emergency Medicine, Providence, United States, ²Emerson Hospital, Department of Emergency Medicine, Concord, United States

PO09.22

Does Pre-travel Self Assessment of Risk Reduce Adverse Events during Medical Electives?

H.C. Bond¹, S.F. Raffe¹, K. Smith², M.L. Schmid¹

¹Royal Victoria Infirmary, Infection & Tropical Medicine, Newcastle upon Tyne, United Kingdom, ²University of Newcastle upon Tyne, Medical School, Newcastle upon Tyne, United Kingdom

PO09.23

The Use of SOAP in Pre-travel Advice

O. Olatunde¹

¹dalhousie university, Family Medicine, Moncton, Canada

PO09.24

Development of the Scottish Malaria Advisory Group 2012

L. Boyne¹, C. Doherty², F. Genasi³, M. Jones³, A. MacConnachie⁴, F. Marra⁵, C. Redman¹, K. Smith¹, H. Sutton¹, M. Urneed⁶

¹Health Protection Scotland, Travel and International Health Team, Glasgow, United Kingdom, ²Royal Hospital for Sick Children, Yorkhill, Paediatric Infectious Disease, Glasgow, United Kingdom, ³Western General Hospital, Regional Infectious Diseases Unit, Edinburgh, United Kingdom, ⁴Gartnavel General Hospital, Brownlee Infectious Diseases Unit, Glasgow, United Kingdom, ⁵Brownlee Infectious Diseases Unit, Pharmacy, Glasgow, United Kingdom, ⁶General Practice, Specialist Nurse Practitioner, Glasgow, United Kingdom

PO09.25

Economics of Malaria Prevention in United States Travelers to West Africa

M.S. Coleman¹, K. Adachi¹, N. Khan², E.S. Jentes³, P. Arguin⁴, S.R. Rao^{5,6}, R.C. LaRocque^{7,8}, M.J. Soti³, G. Brunette⁹, E.T. Ryan^{7,8}, M.I. Meltzer⁹, The Global TravEpiNet Consortium

¹CDC, DGMQ Policy Team, Atlanta, United States, ²CDC, DGMQ, Atlanta, United States, ³CDC, Travelers Health, Atlanta, United States, ⁴CDC, DPDM, Atlanta, United States, ⁵University of Massachusetts Medical School, Department of Quantitative Health Sciences, Worcester, United States, ⁶Bedford MA Medical Center, Center for Health Quality, Outcomes, and Economics Research, Bedford, United States, ⁷Massachusetts General Hospital, Division of Infectious Diseases, Boston, United States, ⁸Harvard Medical School, Department of Medicine, Boston, United States, ⁹CDC, DPEI, Atlanta, United States



Posters, continued

Professional Education and Training

PO10.01

Membership Examination of the Faculty of Travel Medicine (Royal College of Physicians and Surgeons of Glasgow) - Part 2 Objective Structured Clinical Examination

L. Boyne¹, E. Anderson², L. Bramham³, P.L. Chiodini⁴, G. Flaherty⁵, A. Green⁶, A. Grieve¹, V. Hogg⁷, M. Jones⁸, A. McDonald¹, A.W. Todd⁹

¹Royal College of Physicians and Surgeons Glasgow, Faculty of Travel Medicine, Glasgow, United Kingdom, ²NHS Greater Glasgow and Clyde, Public Health Protection, Glasgow, United Kingdom, ³MASTA, Leeds, United Kingdom, ⁴Hospital for Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom, ⁵National University of Ireland, School of Medicine, Galway, Ireland, ⁶Royal Centre for Defence Medicine, Infection Prevention and Control, Birmingham, United Kingdom, ⁷Royal College of Physicians and Surgeons Glasgow, Department of Examinations, Glasgow, United Kingdom, ⁸Western General Hospital, Regional Infectious Diseases Unit, Edinburgh, United Kingdom, ⁹Monklands Hospital, Infection Unit, Airdrie, United Kingdom

PO10.02

Information Overload or News You Can Use: How Nurses View Travel Immunization Resources

G. Rosselot¹, E. Rosenblatt², American Travel Health Nurses Association Board of Directors

¹Travel Well of Westchester, Inc., Briarcliff Manor, United States, ²University of Wisconsin Medical Foundation, Madison, United States

PO10.03

Travel Health and Cultural Awareness of Short Term Volunteers Providing Healthcare in Honduras

K. Avery¹, L. Kennedy Sheldon², R. Martin¹

¹Mount Auburn Hospital, Cambridge, United States, ²University of Massachusetts, Boston, United States

PO10.04

Delegated Tasks and Quality Control in the Collaboration of Nurses and Physicians Active in Travel Clinics in the Netherlands

P.A. de Beer^{1,2}, H.A. Caris³

¹Medical Services for the Tropics Maastricht, Travel Clinics, Maastricht, Netherlands, ²365-Center for Infection Prevention (CIP) and Travel Clinics, Utrecht, Netherlands, ³365-Center for Infection Prevention (CIP) and Travel Clinics, utrecht, Netherlands

PO10.05

Improving Travel Medicine Education at a Multi-disciplinary US Healthcare Company

S.A. McDevitt¹, D. Keane²

¹Walgreens - Take Care Health Systems, Product Solutions, New York, United States, ²Walgreens - Take Care Health Systems, Corporate Health, New York, United States

PO10.06

The Travel Health Advisory Group, Australia: A Joint Travel Industry and Travel Health Special Interest Group Promoting Healthy Travel

P.A. Leggat¹, Travel Health Advisory Group, Australia

¹James Cook University, Discipline of Public Health and Tropical Medicine, Townsville, Australia

Returning Travellers

PO11.01

The Risk Factors of the Colonization of Extended-Spectrum β -Lactamase Producing *Escherichia coli* in the Stools of Returning Japanese Travelers: A Retrospective Case-Control Study

K. Yaita¹, T. Suzuki¹, Y. Yoshimura¹, N. Tachikawa¹

¹Yokohama Municipal Citizen's Hospital, Division of Infectious Diseases, Yokohama, Japan

PO11.02

Schistosomiasis among Returned Travellers: A Continuing Underestimated Condition

A. Goorhuis¹, A. Bart², T. van Gool², M. van Vugt¹, C. Stijnen¹, M.P. Grobusch¹, P.P. van Thiel¹

¹Academic Medical Center, Infectious Diseases and Tropical Medicine, Amsterdam, Netherlands, ²Academic Medical Center, Parasitology, Amsterdam, Netherlands



Posters, continued

PO11.03

Suggestive Paradoxical Reactions after Treatment with Praziquantel in Two Asymptomatic Travelers with Chronic Stage of Schistosomiasis

P. Soentjens^{1,2}, A. Aerssens¹, E. Bottieau²

¹Military Hospital Queen Astrid, Polyclinic Department, Brussels, Belgium, ²Institute of Tropical Medicine, Department of Clinical Sciences, Antwerp, Belgium

PO11.04

Seroprevalence of Schistosomiasis in Scottish School Groups Returning from Sub-Saharan Africa

C.C. Smith¹, C. Redman¹, F. Genasi¹

¹Health Protection Scotland, Travel and International Health, Glasgow, United Kingdom

PO11.05

Acute Schistosomiasis: A Risk Underestimated by Travelers and a Diagnostic Challenge for Medical Practitioners

L. Rochat Stettler¹, A. Bizzini², N. Senn³, P.-Y. Bochud², S. de Vallière¹

¹University Hospital, Travel Clinic, Department of Ambulatory Care and Community Medicine, Lausanne, Switzerland, ²University Hospital, Division of Infectious Diseases, Lausanne, Switzerland, ³University Hospital, Department of Ambulatory Care and Community Medicine, Lausanne, Switzerland

PO11.06

Diagnosis of Travel-related *Schistosoma mansoni* Infection in a Cohort of 21 Subjects

P. Soentjens^{1,2}, L. Cnops¹, W. Peetermans³, R. Mertens⁴, J. Van der Hilst^{5,6}, A. Van Gompel¹, E. Van Wijngaerden³, M. Van Esbroeck¹

¹Institute of Tropical Medicine, Department of Clinical Sciences, Antwerp, Belgium, ²Military Hospital Queen Astrid, Polyclinic Department, Brussels, Belgium, ³Internal Medicine, Universitaire Ziekenhuizen Leuven, KU Leuven, Leuven, Belgium, ⁴Vrije Universiteit Brussel, Internal Medicine - Infectiologie, Brussels, Belgium, ⁵Jessa Hospital, Department of Infectious Diseases and Immunity, Hasselt, Belgium, ⁶University of Hasselt, BIOMED, Diepenbeek, Belgium

PO11.07

Gastrointestinal Illnesses during and after Travel among Boston-Area International Travelers

P.V. Han¹, L.H. Chen^{2,3}, M.E. Wilson⁴, E.S. Jentes¹, C.M. Benoit⁵, W.B. Macleod^{6,7}, R.J. Stoney¹, D.H. Hamer^{5,7,8}, E.D. Barnett⁹, Boston Area Travel Medicine Network

¹Centers for Disease Control and Prevention, Division of Global Migration and Quarantine, Atlanta, United States, ²Mount Auburn Hospital, Travel Medicine Center, Cambridge, United States, ³Harvard Medical School, Boston, United States, ⁴Harvard School of Public Health, Global Health and Migration, Boston, United States, ⁵Boston Medical Center, Maxwell Finland Laboratory for Infectious Diseases, Boston, United States, ⁶Boston University, Center for Global Health and Development, Boston, United States, ⁷Boston University School of Public Health, International Health, Boston, United States, ⁸Boston University School of Medicine, Infectious Diseases, Boston, United States

PO11.08

A Returning Traveller with Congo Crimean Haemorrhagic Fever: Challenges and Lessons

A. MacConnachie¹, D. Barr¹, D. Bell¹, R. Fox¹, M. Jacobs², I. Cropley², S. Hopkins², N. Dawood², C. Aitken³, C. Brown⁴, T. Brooks⁵, S. Ahmed⁵, B. Jeffs¹

¹Brownlee Infectious Diseases Unit, Glasgow, United Kingdom, ²Royal Free NHS London Foundation Trust, London, United Kingdom, ³West of Scotland Specialist Virology Centre, Glasgow, United Kingdom, ⁴Health Protection Agency, Porton Down, United Kingdom, ⁵Department of Public Health, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom

PO11.09

Hepatitis A with Delayed Elevation in the Serum Hepatitis A Virus-specific Immunoglobulin M Antibody Titer: A Case Report and Literature Review

J. Sugihara¹, Y. Kato¹, K. Takahashi², Y. Yanagawa¹, M. Ujijie¹, N. Takeshita¹, S. Kanagawa¹, N. Ohmagari¹, S. Mishiro²

¹National Center for Global Health and Medicine, Disease Control and Prevention Center, Tokyo, Japan, ²Toshiba General Hospital, Department of Medical Sciences, Tokyo, Japan

PO11.10

Diagnosis and Management of Travellers Returning from a Developing Country

P. Zimmermann¹, K. Mühlethaler¹, H. Furrer¹

¹University Hospital, Department of Infectious Diseases, Bern, Switzerland



Posters, continued

PO11.11

Common-sense Interpretation and Application of An International Treaty: Applying International Health Regulations At Points of Entry

C.A. Redman¹, J. Hart², A. Wilson³, N. Black⁴, K. Smith⁵
¹Health Protection Scotland, Glasgow, United Kingdom, ²Public Health Wales, Mold, United Kingdom, ³Public Health Agency Northern Ireland, Belfast, United Kingdom, ⁴Health Protection Agency, Newcastle, United Kingdom, ⁵Health Protection Scotland, Medical Lead - Travel Health, Glasgow, United Kingdom

PO11.12

Leishmaniasis Acquired by Travellers to Endemic Regions in Europe - a EuroTravNet Multi-Centre Study

J.P. Cramer^{1,2}, U. Ehehalt¹, M. Schunk³, M. Jensenius⁴, P.J.J. van Genderen⁵, E. Gkrania-Klotsas⁶, F. Chappuis⁷, P. Schlagenhaufer⁸, R. Lopez-Velez⁹, P. Parola¹⁰, G.D. Burchard^{1,2}
¹University Medical Center Hamburg-Eppendorf (UKE), Section Tropical Medicine, Hamburg, Germany, ²Bernhard Nocht Institute for Tropical Medicine (BNITM), Clinical Research, Hamburg, Germany, ³Ludwig-Maximilians University of Munich, Department of Infectious Diseases and Tropical Medicine, Munich, Germany, ⁴Oslo University Hospital and University of Oslo, Department of Infectious Diseases, Oslo, Norway, ⁵Harbor Hospital, Institute for Tropical Diseases, Rotterdam, Netherlands, ⁶Addenbrooke's Hospital, Department of Infectious Diseases, Cambridge, United Kingdom, ⁷Geneva University Hospitals and University of Geneva, Geneva, Switzerland, ⁸University of Zurich Centre for Travel Medicine, Division of Epidemiology and Communicable Disease, Institute for Social and Preventive Medicine, Zurich, Switzerland, ⁹Hospital Universitario Ramón y Cajal, Tropical Medicine and Clinical Parasitology, Infectious Diseases Department, Madrid, Spain, ¹⁰Aix-Marseille-Université and Assistance Publique-Hôpitaux de Marseille, University Hospital Institute in Infectious Diseases, Tropical Medicine Unit, Marseille, France

PO11.13

Melioidosis: A Case Report in a Returning Traveler from Singapore

S. Amadasi¹, S. Dal Zoppo¹, L. Signorini¹, F. Castelli¹
¹University Division of Tropical Medicine and Infectious Diseases, Brescia, Italy

PO11.14

HIV and Hepatitis A, B and C Screening in Patients Admitted with Imported Malaria

A.S. Santos^{1,2}, C. Abreu^{1,2}, A. Sarmento^{1,2}
¹Hospital S João, Infectious Diseases, Porto, Portugal, ²Medical School, Porto, Portugal

PO11.15

Usefulness of Influenza Rapid Diagnostic Tests for the Management of Travellers Returning with Fever: a Randomized Controlled Study

D. Berthod^{1,2}, B. Genton^{1,2,3}, J. Blum³, C. Hatz³, S. de Vallière¹
¹Travel Clinic, Department of Ambulatory Care and Community Medicine, University Hospital, Lausanne, Switzerland, ²Division of Infectious Diseases, University Hospital, Lausanne, Switzerland, ³Swiss Tropical and Public Health Institute, Basel, Switzerland

PO11.16

Medical Tourism: Infection with Acid Fast Bacteria after Cosmetic Breast Surgery in India

C.D. Vinnemeier¹, A. Wawrzyniak², G.D. Burchard³, S. Schmiedel¹, J.P. Cramer¹
¹University Medical Center Hamburg-Eppendorf (UKE), Section Tropical Medicine, Hamburg, Germany, ²Department of Tropical Medicine at the Bernhard Nocht Institute, German Armed Forces Hospital of Hamburg, Hamburg, Germany, ³Bernhard Nocht Institute for Tropical Medicine (BNITM), Tropical Medicine, Hamburg, Germany

PO11.17

Infections in Returning Travellers to Vancouver/Victoria BC Tropical Medicine Group

W.G. Ghesquiere¹, P. Doyle², Y. Mirzanejad³, M. Imperial⁴, M. Payne⁴, Tropical Medicine Group, BC
¹Vancouver Island Health Authority, University of British Columbia, Medicine, Division of Infectious Diseases, Victoria, Canada, ²Vancouver General Hospital, University of British Columbia, Vancouver, Canada, ³Fraser Health Authority, University of British Columbia, Surrey, Canada, ⁴University of British Columbia, Vancouver, Canada

PO11.18

Travel-associated Primary Skin Melioidosis

J.F. Beert¹, B. De Smet², E. Van den Enden², P. Wattiau³, J. Steenbergen¹, M. Stalpaert¹, F. Van Gompel², J. Jacobs², E. Vlieghe²
¹Algemeen Medisch Laboratorium, Department of Microbiology, Antwerp, Belgium, ²Institute of Tropical Medicine, Department of Clinical Sciences, Antwerp, Belgium, ³Highly Pathogenic & Foodborne Zoonoses, Veterinary and Agrochemical Research Center, Brussels, Belgium



Posters, continued

PO11.19

Occurrence of Pulmonary Complications in Murine Typhus May Be Associated with Geographic Region

T.W. van der Vaart¹, M. van Vugt¹, C. Stijns¹, M.P. Grobusch¹, P.P. van Thiel¹, A. Goorhuis¹

¹Academic Medical Center/ University of Amsterdam, Infectious Diseases and Tropical Medicine, Amsterdam, Netherlands

PO11.20

NS1 Antigen Testing for the Diagnosis of Dengue in Returned Israeli Travelers

J.N. Fuchs¹, H. Bin², S. Schlesinger², E. Schwartz²

¹The Pediatric Infectious Disease Unit, Soroka University Medical Center, Ben-Gurion University, Beer Sheva, Israel, ²National Center for Zoonotic Viruses, Central Virology Laboratory, Ministry of Health, Public Health

Services, Sheba Medical Center, Tel Hashomer, Israel, ³Center for Geographic Medicine and Tropical Diseases Sheba Medical Center, Tel Hashomer, Israel

PO11.21

Dengue Fever in Travelers from a Non Endemic Country

C. Perret¹, E. Balcells¹, C. Vizcaya¹, T. Hirsch¹, T. Azócar², C. Martínez², L. Montecinos², M. Ferrés¹

¹Pontificia Universidad Católica de Chile, School of Medicine, Santiago, Chile, ²Pontificia Universidad Católica de Chile, Virology Laboratory, Santiago, Chile

Trauma, Injury, Security

PO12.01

Studies on Anti-inflammatory, Anti-oxidant and Wound Healing Properties of the Tea Fungus, Kombucha

J.A. Ofori¹, G.A. Larbie¹, P. Adodo², A. Ocloo¹, M.F. Ofori², W.S.K. Gbewonyo¹

¹University of Ghana, Biochemistry, Cell and Molecular Biology, Accra, Ghana, ²Noguchi Memorial Institute for Medical Research, Animal Experimentation, Accra, Ghana, ³Noguchi Memorial Institute for Medical Research, Immunology, Accra, Ghana

Travel Medicine Practice

PO13.01

The Certificate of Fitness to Fly

V. Mera¹, L. Cebrián²

¹Clinica Benidorm, Internal Medicine, Benidorm, Spain, ²Clinica Britannia, Travel Medicine, Calpe, Spain

PO13.02

Epidemiological Characteristics of Long-Term Travelers Around the World in Kurume University Hospital, Japan

H. Hidaka¹, H. Watanabe¹

¹Division of Infectious Diseases, Department of Infectious Medicine, Kurume University School of Medicine, Kurume, Japan

PO13.03

Travel Medicine in Mexico - First Clinic

D.A. Rivera-Avila¹, X. Vite-Velázquez¹, I. Cortes-Tapia¹, L.M. Uribe-Castro¹, P.A. Reyes¹, B. Diaz-Ramirez¹

¹Clinica de Atención Preventiva del Viajero, UNAM, Research Division, Mexico City, Mexico

PO13.04

What Kind of Clients Should Be Targeted On? Seven-month Experience of a Brand New Travel Clinic in Japan

M. Norizuki¹, S. Iwamoto², E. Kusumi², Y. Morisawa¹

¹Jichi Medical University, Center for Clinical Infectious Diseases, Shimotsuke, Japan, ²Navitas Clinic Kawasaki, Kawasaki, Japan

PO13.05

Medical Specialty Impacts Delivery of Travel Medicine Services

P.W. Hickey^{1,2}, D.C. Girasek¹, M. Salisu¹, T.D. Gleeson³

¹Uniformed Services University, Preventive Medicine, Bethesda, United States, ²Uniformed Services University, Pediatrics, Bethesda, United States, ³Uniformed Services University, Internal Medicine, Bethesda, United States

PO13.06

ISTM Member Survey on Sustainable Tourism: A Preliminary Report

M.P. Muehlenbein¹, G. Brink², ISTM Destination Communities Support Interest Group



Posters, continued

¹Indiana University, Anthropology, Bloomington, United States, ²ISTM Destination Communities Support Interest Group, Durban, South Africa

PO13.07

Assistance Medicine - A New Sub-Specialty in Travel Medicine - First Approach to Post-graduate Education and a Medical Curriculum in Germany

S. Esser¹, K. Sickmann¹

¹International SOS, Central Europe Medical Department, Neu-Isenburg, Germany, ²Volkswagen AG, Medical Department, Wolfsburg, Germany

PO13.08

Travel Health Knowledge, Attitude and Practices among Zimbabwean Travellers

S.E.T. Mba¹

¹University of Zimbabwe, Harare, Zimbabwe

PO13.09

New and Emerging Hazards Surveillance; Travel Medicine Expertise applied in Health Protection

C.A. Redman¹, F. Genasi¹, H. Sutton¹

¹Health Protection Scotland, Glasgow, United Kingdom

PO13.10

Implementation of a Multidisciplinary Health Travel Program in the University of Campinas (UNICAMP) - Brazil

M.C.C. Del Monte¹, I.D.C. Guerreiro¹, M.H.P. Pavan¹, P.A.T. Leme¹, R.T. Mendes¹, R.C.G. Trevisane¹, T.M. Nien¹

¹Universidade Estadual de Campinas, Campinas, Brazil

PO13.11

Compliance in Travel Medicine Consultation in Brazil: A Pilot Study

K.M.P. Rodrigues¹, F.S.V. Martins¹

¹Universidade Federal do Rio de Janeiro, Cives (Centro de Informação em Saúde para Viajantes), Rio de Janeiro, Brazil

PO13.12

Evolution of the Pre Travel Consultations in the North of Portugal during the Period from 2002 to 2011

G. Saldanha¹, S. Barbosa¹, A. Silva¹, I. Cruz¹, A. Cardoso¹, N. Rodrigues², D. Antunes¹

¹Sanidade Internacional CVI Porto, Porto, Portugal, ²Sanidade Internacional CVI Matosinhos, Matosinhos, Portugal

PO13.13

Rethinking Standby Emergency Treatment for Malaria: Acute Respiratory Distress Syndrome Despite Treatment of Uncomplicated Malaria in Returned Travelers

K.R. Tan¹, P.M. Arguin¹

¹Centers for Disease Control and Prevention, Atlanta, United States

Japanese Encephalitis

PO14.01

Long-Term Data on Cross-reactive Immunity after Primary and Booster Vaccinations against Japanese Encephalitis

E.O. Erra^{1,2}, H. Hervius Asklung³, S. Yoksan⁴, L. Rombo^{3,5}, J. Riutta⁶, S. Vene⁷, L. Lindquist³, O. Vapalahti^{1,8,9}, A. Kantele^{1,2,6}

¹Haartman Institute, University of Helsinki, Helsinki, Finland, ²Helsinki University Central Hospital, Division of Infectious Diseases, Department of Medicine, Helsinki, Finland, ³Karolinska Institutet, Department of Medicine, Unit for Infectious Diseases, Stockholm, Sweden, ⁴Institute of Molecular Biosciences, Mahidol University, Nakhon Pathom, Thailand, ⁵Centre for Clinical Research, Skåne County Council, Eskilstuna, Sweden, ⁶Travel Clinic, Postitalo, Lääkärikeskus Aava, Helsinki, Finland, ⁷Swedish Institute for Communicable Disease Control, Solna, Sweden, ⁸HUSLAB, Division of Virology and Immunology, Helsinki University Central Hospital, Helsinki, Finland, ⁹University of Helsinki, Department of Veterinary Biosciences, Helsinki, Finland

PO14.02

Reduced Vaccination Rate against Japanese Encephalitis at a Norwegian Vaccination Clinic after Introduction of Ixiaro®

R. Raastad¹, L. Heier¹, G. Hasle¹

¹Oslo Travel Clinic, Oslo, Norway



Posters, continued

PO14.03

Antibody Persistence in Children and Immunogenicity and Safety of A Booster Dose of the Inactivated Japanese Encephalitis Vaccine IXIARO® , IC51

K.L. Dubischar-Kastner¹, V. Kadlecik², B. Sablan Jr², C.F. Borja-Tabora³, S. Gatchalian⁴, S. Eder¹, K. Westritschnig

¹Intercell AG, Vienna, Austria, ²University of the Philippines, Philippine General Hospital, Department of Pediatrics, Manila, Philippines, ³Research Institute for Tropical Medicine, Department of Health, Manila, Philippines, ⁴University of the Philippines, Manila, Philippines

PO14.04

Immunogenicity and Safety of the Inactivated Japanese Encephalitis Vaccine IXIARO® , IC51, in Elderly

K.L. Dubischar-Kastner¹, J.P. Cramer², S. Eder¹, T. Jelinek³, B. Jilma⁴, H. Kollaritsch⁵, E. Reisinger⁶, K. Westritschnig

¹Intercell AG, Vienna, Austria, ²University Medical Center Hamburg-Eppendorf (UKE), Department of Internal Medicine, Section Tropical Medicine / Infectious Diseases, Hamburg, Germany, ³Berlin Center for Travel & Tropical Medicine, Berlin, Germany, ⁴Medical University Vienna, Department of Clinical Pharmacology, Vienna, Austria, ⁵Medical University Vienna, Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Vienna, Austria, ⁶University of Rostock, Department of Tropical Medicine & Infectious Diseases, Rostock, Germany

PO14.05

Post-marketing Safety Profile of the Inactivated Japanese Encephalitis Vaccine IXIARO® - Experience Three Years after Launch

Z. Müller¹, K.L. Dubischar-Kastner¹, R. Hennig², K. Westritschnig¹

¹Intercell AG, Vienna, Austria, ²SCRATCH Pharmacovigilance GmbH, Butzbach, Germany

Rabies

PO15.01

Frequency of and Responses to Potential Rabies Exposures in Peace Corps Volunteers, 2011

K. Harvey¹, E.S. Jentes¹, M. Charles², B. Petersen³, K. Johnson¹, J. Blanton², M.J. Sotir¹, G. Brunette¹

¹Centers for Disease Control and Prevention, Division of Global Migration and Quarantine, Atlanta, United States, ²Peace Corps, Office of Medical Services, Washington, United States, ³Centers for Disease Control and Prevention, Division of High Consequence Pathogens and Pathology, Atlanta, United States

PO15.02

Immunogenicity of a Modified Intradermal Pre-exposure Rabies Vaccination Schedule Using a Purified Chick Embryo Cell Vaccine (Rabipur)

C. Lau^{1,2}, N. Hohi^{3,4,5}

¹University of Queensland, Queensland Children's Medical Research Institute, Brisbane, Australia, ²Travel Medicine Alliance Clinics, Perth and Brisbane, Australia, ³Griffiths University, School of Medicine, Gold Coast, Australia, ⁴Bond University, Faculty of Medicine, Gold Coast, Australia, ⁵Travel Medicine Alliance Clinics, Gold Coast, Australia

PO15.03

Rabies Post Exposure Consultations in New Zealand 1998-2012

M. Shaw¹, J.T. Visser², C. Edwards²

¹James Cook University, Townsville, School Public Health, Auckland, New Zealand, ²University of Otago, Primary Health Care & General Practice, Wellington, New Zealand

PO15.04

Young Short-Term Travelers are at Potential Risk of Rabies

E. Rowe¹, F. Dimatac¹, C.J. Go¹, P.L. Lim¹

¹Tan Tock Seng Hospital, Infectious Diseases, Singapore, Singapore

PO15.05

Case Series of Animal Bites Obtained by Patients in a Japanese Hospital When They Were Abroad

N. Takeshita¹, Y. Kato¹, S. Kutsuna¹, M. Ujiie¹, K. Hayakawa¹, S. Kanagawa¹, N. Ohmagari¹

¹National Center for Global Health and Medicine, Disease Control and Prevention Center, Tokyo, Japan



Posters, continued

A Comparative Study on Efficacy of Purified Chick Embryo Cell Rabies Vaccine (Rabipur®) as a Pre-exposure Prophylaxis for the Japanese, Administering Three Doses on Days 0, 7, 21 or 28 and Three Doses on Days 0, 30, 180

N. Mishima^{1,2}, M.J. Yoshikawa³, T. Shimono¹, I. Nakatani^{1,2}, H. Ishizaki², M. Miyake¹, S. Kanda¹, T. Nishiyama^{1,2}
¹Kansai Medical University, Department of Public Health, Hirakata, Japan, ²Kansai Medical University Takii Hospital, Center for Travel Medicine, Moriguchi, Japan, ³Kyoto University, Inter-Graduate School Unit for Sustainable Development and Survival Societies, Center for the Promotion of Interdisciplinary Education and Research, Kyoto, Japan

Yellow Fever

PO16.01

Yellow Fever Vaccination at Mexico's Traveler Preventive Care Clinic - First Year

D.A. Rivera-Avila¹, X. Vite-Velázquez¹, I. Cortes-Tapia¹, L.M. Uribe-Castro¹, P.A. Reyes¹, B. Diaz-Ramírez¹
¹Clinica de Atención Preventiva del Viajero, UNAM, Research Division, Mexico City, Mexico

Other Immunizations

PO17.01

From 'Non-responders' to 'Poor-responders' - Successful Use of Multi-site Intradermal Hepatitis B Vaccination

A.D. McCallum¹, M.E. Jones¹
¹NHS Lothian, Regional Infectious Diseases Unit, Edinburgh, United Kingdom

PO17.02

A Double Dose Hepatitis B Vaccination Schedule in Travellers Presenting for Late Consultation

S.L. Hollenberg¹, J. Wong², M.K. Payne³
¹University of British Columbia, Department of Family Medicine, Vancouver, Canada, ²University of British Columbia, School of Population and Public Health, Vancouver, Canada, ³University of British Columbia, Pathology and Laboratory Medicine, Vancouver, Canada

PO17.03

Meningococcal Vaccination Patterns of Travelers from Greece Visiting Sub-Saharan Africa

A. Pavli¹, A. Spilioti¹, P. Smeti¹, V. Silvestros², F. Antoniadou³, A. Gregoraki³, H. Maltezou²
¹Hellenic Centre for Disease Control and Prevention, Travel Medicine Office, Athens, Greece, ²Hellenic Centre for Disease Control and Prevention, Department for Interventions in Health Care Facilities, Athens, Greece, ³Regional Department of Public Health and Social Welfare, Athens, Greece

PO17.04

Antibody Persistence 4 Years after a Single Dose of a Quadrivalent Meningococcal ACWY Tetanus Toxoid Conjugate Vaccine in Adolescents and Adults

C. Borja-Tabora¹, C. Montalban², Z.A. Memish³, V. Bianco⁴, M. Van der Wielen⁴, J.M. Miller⁵
¹Research Institute for Tropical Medicine, Muntinlupa City, Philippines, ²Philippine General Hospital, Manila, Philippines, ³College of Medicine, Alfaisal University, Riyadh, Saudi Arabia, ⁴GlaxoSmithKline Vaccines, Wavre, Belgium, ⁵GlaxoSmithKline Vaccines, King of Prussia, United States

PO17.05

The First Norovirus Bivalent GI.1/GII.4 Virus-like Particle (VLP) Vaccine in Man

P. Mendelman¹, J. Treano², S. Frey³, R. Gormley⁴, R. Atmar⁵, D. Topham⁶, W. Chen⁶, J. Ferreira⁷, R. Bargatzte¹, C. Richardson¹
¹Takeda Pharmaceuticals Inc, Vaccines, Bozeman, United States, ²University of Rochester Medical Center, Rochester, United States, ³Saint Louis University, School of Medicine, Saint Louis, United States, ⁴Navy Medical Research Center, Silver Springs, United States, ⁵Baylor College of Medicine, Houston, United States, ⁶University of Maryland School of Medicine, Baltimore, United States, ⁷The EMMES Corporation, Rockville, United States

PO17.06

Factors Determining the Uptake of MMR Vaccination among Korean International Travelers: Focus on Measles Outbreaks in Europe

S.Y. Shin¹
¹Korea Medical Institute, Seoul, Korea, Republic of

PO17.07

Hepatitis A Serologic Screening in Travellers: An evaluation '10 years after'

B. Ngo¹, R. Cartuyvels¹, K. Magerman¹, I. Geysens², J. van der Hilst², A. Mewis¹
¹JESSA Hospital, Laboratory Medicine, Hasselt, Belgium, ²JESSA Hospital, Infectious Diseases, Hasselt, Belgium



Posters, continued

PO17.08

Hepatitis a Vaccination Coverage and International Travel among US-born and Foreign-born Adults

T.J. Cunningham¹, J.A. Singleton², T.V. Murphy³, C.M. Brown¹, G. Brunette⁴

¹Division of Global Migration and Quarantine, Centers for Disease Control and Prevention, Atlanta, United States,

²Immunization Services Division, Centers for Disease Control and Prevention, Atlanta, United States, ³Division of

Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, United States, ⁴Travelers' Health Branch,

Centers for Disease Control and Prevention, Atlanta, United States

PO17.09

Influenza Vaccination Uptake among Australian Hajj Pilgrims in 2011

O. Barasheed¹, H. Rashid¹, I. Ridda^{1,2}, L. Heron¹, D. Dwyer^{2,3,4}, R. Booy^{1,2,3}, Hajj Research Team

¹National Centre for Immunisation Research and Surveillance, Westmead, Australia, ²The University of Sydney,

Sydney Medical School, Sydney, Australia, ³The University of Sydney, Sydney Emerging Infections and

Biosecurity Institute, Sydney, Australia, ⁴Westmead Hospital, Centre for Infectious Diseases and Microbiology

Laboratory Services, Westmead, Australia

Dengue

PO18.01

Dengue Surveillance by Proxy: Travellers as Sentinels for Outbreaks in the Pacific Islands

C. Lau^{1,2}, P. Weinstein², D. Slaney⁴

¹University of Queensland, Brisbane, Australia, ²Travel Medicine Alliance Clinics, Perth and Brisbane, Australia,

³University of South Australia, Barbara Hardy Institute, Adelaide, Australia, ⁴Institute of Environmental Science

and Research, Porirua, New Zealand

PO18.02

Dengue Virus Infection in Bali, Indonesia: A Continued Challenge to a Tropical Tourist Destination

M.J. Yoshikawa¹, R. Kusriastuti², A. Suwandono^{3,4}, N. Mishima^{5,6}, T. Nishiyama^{5,6}

¹Kyoto University, Center for the Promotion of Interdisciplinary Education and Research, Inter-Graduate School

Unit for Sustainable Development and Survivable Societies, Kyoto, Japan, ²Ministry of Health, Directorate

General of Disease Control and Environmental Health, Vector Borne Disease Control, Jakarta, Indonesia,

³Diponegoro University, School of Public Health, Semarang, Indonesia, ⁴Ministry of Health, National Institute of

Health Research and Development, Jakarta, Indonesia, ⁵Kansai Medical University Takii Hospital, Center for

Travel Medicine, Hirakata, Japan, ⁶Kansai Medical University, Department of Public Health, Hirakata, Japan

PO18.03

Intended Mosquito Avoidance Practices International Travel Behavior Model (IMAP-ITB) for Dengue Prevention in U.S. Travelers

K.C. Allen¹

¹Kent State University, College of Public Health, Kent, United States

PO18.04

Half Century of Dengue in Thailand

A. Tawatsin¹, U. Thavara¹, J. Chompoonsri¹, P. Bhakdeenuan¹, S. Anantapreecha¹, S. Sangkitporn¹, P.

Siriyasatien², P. Asavadachanukorn³

¹National Institute of Health, Department of Medical Sciences, Nonthaburi, Thailand, ²Department of Parasitology,

Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, ³Department of Statistics, Faculty of

Commerce and Accountancy, Chulalongkorn University, Bangkok, Thailand

PO18.05

Identification of High Risk Areas for DHF in Thailand

U. Thavara¹, A. Tawatsin¹, J. Chompoonsri¹, P. Bhakdeenuan¹, S. Sangkitporn¹, A. Phumee², P. Siriyasatien², P.

Asavadachanukorn³

¹National Institute of Health, Department of Medical Sciences, Nonthaburi, Thailand, ²Department of Parasitology,

Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, ³Department of Statistics, Faculty of

Commerce and Accountancy, Chulalongkorn University, Bangkok, Thailand



Posters, continued

PO18.06

High Prevalence Rate of Previous Dengue Virus Infection among First Generation Surinamese Immigrants in The Netherlands

F.W. Overbosch¹, A. van den Hoek^{1,2}, J. Schinkel³, G.J. Sonder^{1,2,4}

¹Public Health Service (GGD), Department of Infectious Diseases, Amsterdam, Netherlands, ²Academic Medical Center, Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, Amsterdam, Netherlands, ³Academic Medical Center, Department of Medical Microbiology, Section of Clinical Virology, Amsterdam, Netherlands, ⁴National Coordination Centre for Traveller's Health Advice (LCR), Amsterdam, Netherlands

Malaria

PO19.01

An Unusual Case of Non-Falciparum, Non-Vivax Malaria in Singapore Presenting as Dengue Fever

R.K.C. Fong¹

¹Changi General Hospital, Department of Medicine, Division of Infectious Diseases, Singapore, Singapore

PO19.02

Malaria Prevention Strategies: Adherence among Boston-Area Travelers Visiting Malaria-endemic Countries

R.J. Stoney¹, L.H. Chen^{2,3}, E.S. Jentes¹, M.E. Wilson⁴, P.V. Han¹, C.M. Benoit⁵, W. Macleod^{6,7}, D.H. Hamer^{6,7,8}, E.D. Barnett¹, Boston Area Travel Medicine Network

¹Centers for Disease Control and Prevention, Division of Global Migration and Quarantine, Atlanta, United States,

²Mount Auburn Hospital, Travel Medicine Center, Cambridge, United States, ³Harvard Medical School, Boston, United States, ⁴Harvard School of Public Health, Global Health and Migration, Boston, United States, ⁵Boston Medical Center, Maxwell Finland Laboratory for Infectious Diseases, Boston, United States, ⁶Boston University, Center for Global Health and Development, Boston, United States, ⁷Boston University School of Public Health, International Health, Boston, United States, ⁸Boston University School of Medicine, Infectious Diseases, Boston, United States

PO19.03

Travel-related Cases of Malaria in Quebec, Canada

Y.-G. Bu^{1,2,3}, S. Trépanier⁴, M. Blackburn^{1,3}, F. Milord^{1,3}, É. Levac³

¹Université de Sherbrooke, Public Health, Longueuil, Canada, ²Institut National de Santé Publique Du Québec, Montreal, Canada, ³CSSS Champlain-Charles-Lemoyne, Public Health, Longueuil, Canada, ⁴CSSS Manicouagan, Public Health, Baie-Comeau, Canada

PO19.04

Primaquine Use as the Anti-Malarial Relapse Drug in Japan - Possible Relevance of Body Weight-adjusted Doses to the Drug Efficacy

S. Shimizu¹, T. Kikuchi¹, M. Koga¹, H. Maruyama², M. Kimura³

¹Department of Infectious Diseases and Applied Immunology, Research Hospital of the Institute of Medical Science, University of Tokyo, Tokyo, Japan, ²Department of Infectious Diseases, Division of Parasitology, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan, ³Department of Internal Medicine, Shin-Yamanote Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan

PO19.05

Efficacy and Tolerance of 420 mg Primaquine Radical Cure in Plasmodium vivax Relapses in a Series of Adult French Travelers

C. Rapp^{1,2}, S. Ngo³, C. Ficko³, C. Flateau³, N. Cardon³, O. Aoun³, D. Andriamanantena³, M. Borne Pons³

¹Begin Military Hospital, Infectious and Tropical Diseases, Saint-Mandé, France, ²Ecole du Val de Grâce, Paris, France, ³Begin Military Hospital, Saint-Mandé, France

PO19.06

Hemolytic Anemia Complicating Intravenous Artesunate Treatment in Severe Plasmodium falciparum Malaria: Stay Alert!

C. Rapp^{1,2}, C. Ficko³, C. Flateau³, D. Andriamanantena³, O. Aoun³, J. Henard³

¹Begin Military Hospital, Infectious and Tropical Diseases, Saint-Mandé, France, ²Ecole du Val de Grâce, Paris, France, ³Begin Military Hospital, Saint-Mandé, France

PO19.07

Severe Imported Adults P. falciparum Malaria: Clinical Spectrum and Outcome in 119 Cases

C. Rapp^{1,2}, A. Reggad³, C. Ficko³, C. Flateau³, O. Aoun³, C. de Moreuil³, S. Merat³

¹Begin Military Hospital, Infectious and Tropical Diseases, Saint-Mandé, France, ²Ecole du Val de Grâce, Paris, France, ³Begin Military Hospital, Saint-Mandé, France



Posters, continued

PO19.08

Prognostic Relevance of Conjugated Hyperbilirubinemia in Adults Presenting with Imported *Plasmodium falciparum* Malaria

C. Rapp^{1,2}, C. de Moreuil³, C. Verret⁴, C. Ficko³, O. Aoun³, D. Andriamanantena³, C. Flateau³, P. Imbert³
¹Begin Military Hospital, Infectious and Tropical Diseases, Saint-Mandé, France, ²Ecole du Val de Grâce, Paris, France, ³Begin Military Hospital, Saint-Mandé, France, ⁴CESPA, Paris, France

PO19.09

Detection of Antimalarial Drug Resistance: A Novel and Simple Real-time Sensitivity Assay for *Plasmodium falciparum*

M. Rebelo¹, C. Tempera¹, C. Sousa¹, M.P. Grobusch², T. Hanscheid¹
¹Instituto de Medicina Molecular, Lisboa, Portugal, ²Center for Tropical Medicine and Travel Medicine Department of Infectious Diseases, Division of Internal Medicine Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands

PO19.10

Outbreak of *Plasmodium falciparum* and Ovale Infections in Belgian Military Personnel during and after Deployment in Kinshasa, DRC

P. Soentjens^{1,2}, A. Wauters¹, P. Andries¹, B. Damanet¹, W. Heuninckx³, M. Van Esbroeck⁴, A. Aertsens¹
¹Military Hospital Queen Astrid, Polyclinic Department, Brussels, Belgium, ²Institute of Tropical Medicine, Clinical Sciences, Antwerp, Belgium, ³Military Hospital Queen Astrid, Lab Department, Brussels, Belgium, ⁴Institute of Tropical Medicine, Department of Clinical Sciences, Antwerp, Belgium

PO19.11

A Study of the Biting Pattern within *Anopheles gambiae sensu lato* (s.l.)

S.A. Pi-Bansa^{1,2}, M. Appawu¹, S. Dadzie¹, K. Frempong¹, J.H.N. Osei^{1,2}, M. Wilson¹, O. Danso², D.A. Boakye¹
¹Noguchi Memorial Institute for Medical Research, Parasitology, Accra, Ghana, ²Kwame Nkrumah University of Science and Technology, Theoretical and Applied Biology, Kumasi, Ghana

PO19.12

Malaria Advice for India: Rational Use of Evidence With a Precautionary Approach

C.A. Redman¹, L. Boyne¹, F. Genasi¹, M. Jones², A. Macconnachie³, F. Marra³, C. Doherty⁴, C. Smith¹, H. Sutton¹, M. Umeed⁵
¹Health Protection Scotland, Glasgow, United Kingdom, ²Western General Hospital, Edinburgh, United Kingdom, ³Gartnavel General Hospital, Glasgow, United Kingdom, ⁴Yorkhill Hospital, Glasgow, United Kingdom, ⁵General Practice, Glasgow, United Kingdom

PO19.13

Syndrome of Inappropriate ADH Secretion (SIADH) in Severe Falciparum Malaria: Treatment with Vasopressin Receptor Antagonist (Vaptan)

S. Schmiedel¹, G. Burchard¹
¹University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany

PO19.14

Standby Emergency Treatment (SBET) for Presumptive Malaria: Use in U.S. Clinics Employing Nurse Educators

G. Rosselot¹
¹Travel Well of Westchester, Inc., Briarcliff Manor, United States

PO19.15

Factors Associated with Imported Malaria Give Support to a State of 'Long-Term' Semi-immunity to Malaria in Sub-Saharan African Migrants Living in France

T. Pistone¹, A. Diallo¹, M. Mechain¹, M.-C. Receveur¹, D. Malvy^{1,2}
¹University Hospital Center of Bordeaux, Travel Clinic and Division of Clinical Tropical Medicine, Department of Tropical Diseases, Bordeaux, France, ²Victor Segalen University, Centre René Labusquière, Center for Tropical Medicine, Bordeaux, France

PO19.16

Multidisciplinary I.C.U. Management of Severe *Plasmodium falciparum* Malaria (S.P.F.M)

M.A. Saio¹, F. Mwangera¹
¹Nairobi Hospital, Nairobi, Kenya



Posters, continued

PO19.17

Malaria Prophylaxis Documented in 100 Expatriate Children in Western Africa - A Preliminary Report

M. Felfelnig¹, R. Ruthvin²

¹International SOS, Dubai, United Arab Emirates, ²International SOS, Lagos, Nigeria

Other Vector-borne Infections

PO20.01

Detection of *Leishmania siamensis* DNA in Saliva by Polymerase Chain Reaction

A. Phumee¹, K. Kivichian², S. Chusri³, N. Noppakun^{4,5}, A. Vibhagool¹, V. Sanprasert², H. Wilde⁴, P. Siriviasatien^{2,6}

¹Faculty of Medicine, Chulalongkorn University, Medical Science Program, Bangkok, Thailand, ²Faculty of Medicine, Chulalongkorn University, Department of Parasitology, Bangkok, Thailand, ³Faculty of Medicine, Prince of Songkla University, Department of Medicine, Songkhla, Thailand, ⁴Faculty of Medicine, Chulalongkorn University, Department of Medicine, Bangkok, Thailand, ⁵Bumrungrad International Hospital, Bangkok, Thailand, ⁶King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Excellence Center for Emerging Infectious Diseases, Bangkok, Thailand

PO20.02

Occurrence of Chikungunya Virus in Field-caught Mosquitoes, *Aedes albopictus*, and Virological Feature of Patients with Suspected Chikungunya Fever in Thailand

U. Thavara¹, J. Chompoonsi¹, A. Tawatsin¹, P. Bhakdeenuan¹, A. Phumee², S. Anantapreecha¹, S. Naemkhunthot¹, S. Sangkitporn¹, P. Siriyasatien²

¹National Institute of Health, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand, ²Department of Parasitology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

PO20.03

Severe West Nile Virus Encephalitis in a Patient Repatriated from Djibouti

C. Rapp^{1,2}, C. Ficko³, I. Leparc Goffard⁴, D. Andriamanantena³, C. Fleteau³, O. Aoun³, C. Bigaillon³

¹Begin Military Hospital, Infectious and Tropical Diseases, Saint-Mandé, France, ²Ecole du Val de Grâce, Paris, France, ³Begin Military Hospital, Saint-Mandé, France, ⁴CNR Arbovirus, Marseille, France

PO20.04

Heart Transplantation in Patient with Dilated Cardiomyopathy and *Trypanosoma cruzi* Positive Serology, in Bergamo, Italy

A. Raglio¹, R. Fiocchi², M. Verges³, F. Vailati¹, M. Arosio¹, G. Bargiggia¹, A. Tebaldi⁴, C. Farina¹

¹AO Ospedali Riuniti, USC Microbiologia e Virologia, Dipartimento di Medicina di Laboratorio, Bergamo, Italy, ²AO Ospedali Riuniti, Dipartimento Cardiovascolare, Bergamo, Italy, ³Universidad de Barcelona, Departamento de Parasitología, Barcelona, Spain, ⁴AO Ospedali Riuniti, USC Malattie Infettive, Bergamo, Italy

PO20.05

One Spray for All Biting Bugs? a Literature Review of Repellent Efficacy

E. Lupi¹, C.F. Hatzl¹, P. Schlagenhauf¹

¹University of Zürich, Centre for Travel Medicine, Zürich, Switzerland

Older

PO21.01

Characterisation of Immune Responses to Primary Japanese Encephalitis Vaccination in Elderly Compared to Young Vaccinees

A. Wagner¹, E. Garner-Spitzer¹, J. Jasinska¹, M. Paulke-Korinek¹, M. Hofer¹, H. Kollaritsch¹, F.X. Heinz², U. Wiedermann¹

¹Medical University of Vienna, Institute of Specific Prophylaxis and Tropical Medicine, Vienna, Austria, ²Medical University of Vienna, Department of Virology, Vienna, Austria

Immunocompromised

PO22.01

Yellow Fever Virus Neutralizing Antibodies Persist Despite Longstanding Immunosuppression

L.G. Visser¹, A.W. de Visser², E.F.F. Jonker², D.K. Aaftink³

¹Leiden University Medical Center, Travel Clinic, Department of Infectious Diseases, Leiden, Netherlands, ²Leiden University Medical Center, Department of Infectious Diseases, Leiden, Netherlands, ³KLM Health Services, Schiphol Oost, Netherlands



Posters, continued

PO22.02

Risk Perception about Yellow Fever and Other Infectious Diseases among Travelers with HIV Followed at Hospital for Infectious Diseases Emilio Ribas, in Sao Paulo, SP, Brazil

L. Vieira¹, J. Alves¹

¹Hospital for Infectious Diseases Emilio Ribas, Travel Medicine, Sao Paulo, Brazil

PO22.03

Immunocompromised Travelers from the U.S.: Demographic Characteristics, Travel Destinations, and Pre-travel Health Care from the U.S. Global TravEpiNet Consortium

B. Schwartz¹, J. Rosen², P. Han³, N.A. Hynes⁴, S.R. Rao⁵, E.S. Jentes⁶, R.C. LaRoque⁶, E.T. Ryan⁶, Global TravEpiNet Consortium

¹Travel Medicine and Immunization Clinic, University of California, San Francisco, Division of Infectious Diseases, San Francisco, United States, ²Infectious Diseases and Travel Medicine Clinic, Georgetown University, Division of Infectious Diseases, Washington, United States, ³Centers for Disease Control and Prevention, Division of Global Migration and Quarantine, Atlanta, United States, ⁴Johns Hopkins Travel and Tropical Medicine Clinic, Johns Hopkins School of Medicine, Division of Infectious Diseases, Baltimore, United States, ⁵University of Massachusetts Medical School, Department of Quantitative Health Sciences, Bedford, United States, ⁶Traveler's Advice and Immunization Center, Massachusetts General Hospital, Division of Infectious Diseases and Harvard Medical School, Boston, United States

PO22.04

Trends and Characteristics in HIV-infected and Diabetic Travelers Attending a Travel Clinic before Traveling to the (Sub)Tropics

F. Elfrink^{1,2}, A. van den Hoek^{1,3}, G. Sonder^{1,2,3}

¹Public Health Service (GGD), Department of Infectious Diseases, Amsterdam, Netherlands, ²National Coordination Centre for Traveller's Health Advice (LCR), Amsterdam, Netherlands, ³Department of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and Aids, Academic Medical Center, Amsterdam, Netherlands

Infants/Young Children

PO23.01

Preparing Children for Travel to Developing Countries: A Survey of ISTM Pediatric Interest Group Members

J.C. Christenson¹, P.R. Fischer², S. Hagmann³, E. Leshem^{4,5}, W. Stauffer⁶, E. Barnett⁷, ISTM Pediatric Interest Group

¹Indiana University School of Medicine, Pediatric Infectious Diseases, Indianapolis, United States, ²Mayo Clinic Children's Center, Rochester, United States, ³Albert Einstein College of Medicine, Bronx-Lebanon Hospital Center, New York, United States, ⁴Sheba Medical Center, Department of Internal Medicine C, Tel Hashomer, Israel, ⁵Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁶University of Minnesota School of Medicine, Division of Infectious Diseases and International Medicine, Minneapolis, United States, ⁷Boston Medical Center, Maxwell Finland Laboratory for Infectious Diseases, Boston, United States

PO23.02

Characteristics of Pediatric Travelers Visiting a Travel Clinic at a University Hospital in Tokyo

S. Fukushima¹, Y. Mizuno¹, Y. Yamaguchi¹, T. Hirohata¹, S. Masuyama¹, A. Hamada¹

¹Tokyo Medical University Hospital, Travellers' Medical Center, Shinjuku, Japan

Other Special Needs Travellers

PO24.01

Evaluation of Behaviour Influencing the Start of Malaria Chemoprophylaxis in 154 Travelers to Accra, Ghana

R.W. Wieten¹, P.M.M. Biemond¹, J.W.J. Kalule-Dusseldorp¹, B.J. Visser¹, P.P.A.M. van Thiel¹, C. Stijns¹, A. Goorhuis¹, M.P. Grobusch¹, J. Harting², M. van Vugt¹

¹Academic Medical Center/ University of Amsterdam, Center of Tropical and Travel Medicine, Department of Infectious Diseases, Division of Internal Medicine, Amsterdam, Netherlands, ²Academic Medical Center/ University of Amsterdam, Department of Social Sciences, Amsterdam, Netherlands

PO24.02

Characteristics of Israeli Travelers with Chronic Illness Traveling to Tropical Countries

S. Stienlauf^{1,2,3}, B. Streltsin^{3,4}, E. Kopel^{1,2}, E. Meltzer^{1,2,3}, E. Leshem^{1,2,3}, D. Kurnik^{2,3}, G. Segal^{2,3}, E. Schwartz^{1,2,3}

¹The Sheba Medical Ctr, ²The Travel Clinic & the Center for Tropical Medicine, Tel Hashomer, Israel, ³The Sheba Medical Ctr, Departments of Internal Medicine, Tel Hashomer, Israel, ⁴Tel-Aviv University, Sackler School of Medicine, Tel-Aviv, Israel, ⁵The Sheba Medical Ctr, The Arrow Project, Tel Hashomer, Israel



Sponsored Satellite Program Information



GlaxoSmithKline
Vaccines

GlaxoSmithKline Satellite Symposium & Panel discussion

Monday, 20 May
13.00 – 14.30

Scientific Programme

Meningococcal Vaccination amongst the travel population

Chair: Ghassan Dbaibo

13.00–13.10	Welcome and introduction	Ghassan Dbaibo
Presentation		
13.10–13.40	Quadrivalent conjugate vaccines in the adult and traveller population	Ghassan Dbaibo
Panel discussion 1		
13.40–14.00	Vaccination during outbreaks: recent lessons	Robert Steffen
Panel discussion 2		
14.00–14.20	Vaccinating travellers and pilgrims	Annelies Wilder-Smith
14.20–14.30	Concluding remarks	Ghassan Dbaibo



Novartis Vaccines and Diagnostics Satellite Symposium Program



Novartis Vaccines Satellite Symposium & Panel Discussion

Tuesday, 21 May
13.00 – 14.30

Scientific Programme

Travelling with the next generation – NEWS on JE vaccination

Chair: Professor Robert Steffen

Welcome and introduction	Professor Robert Steffen, University of Zurich, Switzerland
Introducing IXIARO[®] for paediatric use	Katrin Dubischar-Kastner, Intercell AG, Vienna, Austria
Do current JE vaccination recommendations match travellers' risks?	Dr Tomas Jelinek, Berlin Center for Travel and Tropical Medicine, Berlin, Germany
Case reports and discussion	Professor Robert Steffen
Summary and close	Professor Robert Steffen



ISTM Committee and Group Meetings

ISTM Leadership Lounge and Secretariat Office, The Lisbon Room, Level 0, Room 0.7

Sunday, 19 May: 13.00-17.00 **Wednesday, 22 May: 08.00-17.00**

Monday, 20 May: 08.00-17.00 **Thursday, 23 May: 08.00-12.00**

Tuesday, 21 May: 08.00-17.00

Sunday, 19 May - *All meetings held at the MECC.*

WHO Consultation on International Travel and Health (ITH)

By Invitation Only; 10.00-14.00 in The Berlin/Copenhagen Rooms, Level 0, Rooms 0.2/0.3

ISTM Journal of Travel Medicine Editorial Board

By Invitation Only; 14.00-15.30 in Euro Room in the Euro Complex Centre

ISTM Publications Committee

By Invitation Only; 15.30-17.00 in Euro Room in the Euro Complex Centre

ISTM Nurses Reception

Open to All; 15.00-16.30 in The Brussels/Paris Rooms, Level 0, Rooms 04 and 05

ISTM Pharmacists Reception

Open to All; 15.00-16.30 in The Pressroom, Level 0, Room 0.11

Monday, 20 May - *All meetings held at the MECC.*

ISTM Examination Committee

By Invitation Only; 07.00-08.00 in The Rhine Room, Level 2, Room 2.8

ISTM Destination Communities Support Interest Group Council

By Invitation Only; 12.45-14.45 in The Meuse Room, Level 2, Room 2.7

ISTM Pediatric Interest Group Council

By Invitation Only; 12.45-14.45 in The Rhine Room, Level 0, Room 2.8

ISTM Psychological Health of Travellers Interest Group Council

By Invitation Only; 12.45-14.45 in The Euphrates Room, Level 2, Room 2.9

ISTM Destination Communities Support Interest Group General Assembly

Open to All; 18.30-19.15 in The Rome Room, Level 0, Room 0.8

ISTM Pediatric Interest Group General Assembly

Open to All; 18.30-19.15 in The Paris Room, Level 0, Room 0.5

ISTM Psychological Health of Travellers Interest Group General Assembly

Open to All; 18.30-19.15 in The Athens Room, Level 0, Room 0.9



Tuesday, 21 May - *All meetings held at the MECC.*

ISTM Research and Awards Committee

By Invitation Only; 07.00-08.00 in The Meuse Room, Level 2, Room 2.7

ISTM Migrant and Refugee Interest Group Council

By Invitation Only; 12.45-14.45 in The Euphrates Room, Level 2, Room 2.9

ISTM Nursing Professional Group Council

By Invitation Only; 12.45-14.45 in The Rhine Room, Level 2, Room 2.8

ISTM Pharmacist Professional Group Council

By Invitation Only; 12.45-14.45 in The Meuse Room, Level 2, Room 2.7

ISTM Migrant and Refugee Interest Group General Assembly

Open to All; 18.30-19.15 in The Paris Room, Level 0, Room 0.5

ISTM Nursing Professional Group General Assembly

Open to all Nurses; 18.30-19.15 in The Rome Room, Level 0, Room 0.8

ISTM Pharmacist Professional Group General Assembly

Open to all Pharmacists; 18.30-19.15 in The Athens Room, Level 0, Room 0.9

Wednesday, 22 May - *All meetings held at the MECC.*

CISTM13 Scientific Program Committee

By Invitation Only; 07.00-08.00 in The Rhine Room, Level 2, Room 2.8

ISTM Continuing Professional Development Committee

By Invitation Only; 12.45-14.45 in The Meuse Room, Level 2, Room 2.7

ISTM Professional Education Committee

By Invitation Only; 12.45-14.45 in The Rhine Room, Level 2, Room 2.8

ISTM GeoSentinel/EuroTravNet/CanTravNet Network Members

Open to All; 13.15-14.30 in The Rome Room, Level 0, Room 0.8

ISTM Membership Assembly followed by Cocktail Reception

Open to All; 17.15-19.30 in Auditorium 2

Related Society Meetings - *All meetings held at the MECC.*

Asia Pacific Travel Health Society and Scientific Committee Meeting

By Invitation Only; Tuesday, 21 May, 07.00-09.00 in The Euphrates Room, Level 2, Room 2.9

NECTM Steering and Scientific Committee

By Invitation Only; Monday, 20 May, 18.30-20.00 in The Rhine Room, Level 2, Room 2.8



Exhibition

The Exhibits, Posters, and Tea/Coffee Breaks are located on the main level of the MECC in the Expo Foyer from Monday, 20 May through Wednesday, 22 May. The MECC will provide special food outlets to easily purchase lunch within the centre.

Exhibition Schedule:

Sunday, 19 May 2013

Welcome Reception, 18.00-20.00

Monday, 20 May 2013

Exhibits and Posters 10.30-17.00

Tea/Coffee Breaks 10.30-11.15 and 16.15-17.00

Lunch Break 12.45-14.45

Tuesday, 21 May 2013

Exhibits and Posters 10.30-17.00

Tea/Coffee Breaks 10.30-11.15 and 16.15-17.00

Poster Tours 10.30-11.15 and 16.15-17.00

Lunch Break 12.45-14.45

Wednesday, 22 May 2013

Exhibits 10.30-17.15

Coffee Breaks 10.30-11.15 and 16.15-17.15

Lunch Break 12.45-14.45

Poster Session/Authors in Attendance 16.15 - 17.15



Exhibitor List with Exhibition Locations


- Stand 1:** GlaxoSmithKline Vaccines registered as GlaxoSmithKline Biologicals
 - Stand 2:** International Society of Travel Medicine
 - Stand 3:** Crucell
 - Stand 4:** Sigma-Tau S.p.A.
 - Stand 5:** inFact UK Ltd
 - Stand 6:** Sitata Inc.
 - Stand 7:** Novartis Vaccines & Diagnostics, Inc.
 - Stand 8:** tropimed®
 - Stand 9:** Oxford University Press
 - Stand 10:** Bimuno®
 - Stand 11:** Sanofi Pasteur MSD
 - Stand 12:** Centers for Disease Control & Prevention
 - Stand 13:** NECTM
 - Stand 14:** Royal College of Physicians and Surgeons of Glasgow
 - Stand 15:** International SOS
 - Stand 16:** South African Society of Travel Medicine (SASTM)
 - Stand 17:** Shoreland, Inc
-

In the exhibition there is a special area set up for materials about the Travel Medicine Regional Meetings that will be taking place in 2014.

There is also a Free Literature Area in the exhibition where not-for-profit organizations and societies are invited to place their meeting promotional literature.



Exhibition Floor Plan





Exhibitor Information

GlaxoSmithKline Vaccines registered as GlaxoSmithKline Biologicals

Rue de l'Institut 89, 1330 Rixensart, Belgium

Tel: +32 (0)10 85 51 11

Website: www.gsk.com



GlaxoSmithKline is one of the world's leading vaccine companies and a leader in innovation. The company is active in vaccine research, development and production with over 30 vaccines approved and 18 more in development - both in the prophylactic and therapeutic fields. For further information, please visit www.gsk.com

Novartis Vaccines & Diagnostics, Inc.

350 Massachusetts Avenue, Cambridge, MA 02139, USA

Contact Person: Elizabeth Power

Tel: + 1 617 871 7000

Email: nvd.communications@novartis.com

Website: www.novartisvaccines.com



"Caring Begins with Prevention"

At Novartis Vaccines and Diagnostics, we believe that caring for patients begins with protecting individuals and societies from infection in the first place. Our innovative vaccines and diagnostics tools are designed to prevent the spread of life-threatening diseases in order to protect vulnerable populations and keep healthy people healthy.

Bimuno®

5 Canon Harnett Court, Wolverton Mill, Milton Keynes MK12 5NF

Contact Person: Christopher Chrysanthou

Tel: +44 (0)1908 577850

Email: Christopher.chrysanthou@clasaco.com

Website: www.bimuno.com



Clasado researches and develops prebiotics and markets them as scientifically proven gut health supplements, under the brand name Bimuno®. Bimuno® is the only 2nd generation prebiotic and offers additional selectivity and functionality over probiotics and other prebiotics. Bimuno® TRAVELAID was developed to provide nutritional support for holidaymakers and business travellers. www.bimuno.com



Centers for Disease Control & Prevention

1600 Clifton Road E 03, Atlanta, Ga 30333, USA

Contact Person: Kelly Holton

Tel: +1 404 639 2112

Email: nfh5@cdc.gov

Website: www.cdc.gov



The CDC Travelers' Health Branch works to reduce illness and injury in U.S. residents traveling internationally or living abroad. The branch provides travel health advice, including vaccine recommendations and requirements, to international travelers and the health care providers who advise them. The branch produces *CDC Health Information for International Travel*, commonly referred to as the "Yellow Book," the definitive U.S. travel medicine reference for clinicians advising patients before and after travel and is a renowned reference throughout the world. CDC's Travelers' Health website (www.cdc.gov/travel) provides outbreak updates and travel notices, travel-related disease information, and destination-specific recommendations for travelers and their health care providers. The website contains information for specific groups of travelers, such as children, study-abroad students, humanitarian and emergency response workers, and special needs travelers. Additional resources include podcasts, presentations, and a registry of U.S. clinics that provide yellow fever vaccine.

Crucell

Archimedesweg 4-6, 2333 CN Leiden, The Netherlands

Contact Person: Jeannette Jager van Dijk

Tel: +31 (0)71 519 9100

Email: ra-crxnl-info@its.jnj.com

Website: www.crucell.com



Crucell is a global biopharmaceutical company dedicated to bringing meaningful innovation to global health. Our portfolio includes a fully liquid pentavalent vaccine, an aluminum-free hepatitis A vaccine, oral vaccines against typhoid and cholera, and a virosomal adjuvanted vaccine against influenza. Crucell is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.



inFact UK Ltd

Unit 13, Mercury Quays, Ashley Lane,
Shipley, BD17 7DB, UK
Contact Person: Dr Chakib Kara-Zaitri
Tel: +44 (0) 1274 585 365

Email: Chakib@in-Fact.com

Website: www.in-fact.com

inFact UK proudly announce **HPTravel** - A secure web-based software suite for Travel Health and Vaccination, developed with travel health experts. **HPTravel** consists of five integrated modules: Online Booking, Call Centre, Reception, Clinical and Administration. inFact UK have 14 years experience in developing software in Public Health. Please visit <http://HPTravelinfo.in-fact.com>.



International SOS

331 Northbridge Road, #17-00,
Odeon Towers, 188720, Singapore
Contact Person: Diane Hutchinson
Tel: +65 6330 9832

Email: Diane.HUTCHINSON@internationalsos.com

Website: www.internationalsos.com

International SOS is the world's leading provider of medical assistance, international healthcare and security services. Our expertise enables organisations to manage the health risks facing their international travellers and global workforces. We offer our medical professionals the opportunity to develop an exciting international career whilst delivering international standards of healthcare.





Northern European Conference on Travel Medicine (NECTM)

Kongress & Kultur AS, P.O. Boks 947 Sentrum,
N-5008 Bergen, Norway
Contact Person: Pål Voltersvik
Tel: +47 901 05 488

Email: pal.voltersvik@gades.uib.no
Website: www.nectm.com



NECTM was founded in November 2003 and the 1st NECTM was held in Edinburgh in May 2006. Experience from the biannual Scandinavian conferences since 1998 (SFTM) has been useful for NECTM as a regional conference. Since, 3 biannual conferences have been arranged in Helsinki (2008), Hamburg (2010) and Dublin (2012) with 800 – 1000 participants from European countries and also from overseas. Each conference has its own focus; thus the next NECTM in Bergen, Norway, in 2014 should be of particular interest for the delegates to this CISTM as well!

Oxford University Press

Great Clarendon Street, Oxford OX2 6DP, UK
Contact Person: Beth McAllister
Tel: +44 (0) 1865 556767

Email: beth.mcallister@oup.com
Website: www.global.oup.com



Oxford University Press publishes some of the most respected medical content in the world, including titles such as *CDC Health Information for International Travel*, *Travellers' Health: How to stay healthy abroad* and the *Oxford Textbook of Medicine: Infection*. Visit our stand to browse books and enjoy an exclusive conference discount.

Royal College of Physicians and Surgeons of Glasgow

232-242 St Vincent Street, Glasgow, G25RJ, UK
Contact Person: Muir Brown
Tel: +44 (0) 141 221 6072

Email: muir.brown@rcpsg.ac.uk
Website: www.rcpsg.ac.uk



ROYAL COLLEGE OF
PHYSICIANS AND
SURGEONS OF GLASGOW

The Royal College of Physicians and Surgeons of Glasgow is the only multidisciplinary Royal College in the UK and home to the Faculty of Travel Medicine. We provide high quality education, training, professional development, examinations and assessment to more than 10,000 members worldwide, including medical and non-medical specialists in travel medicine.



Sanofi Pasteur MSD

Sanofi Pasteur MSD The Netherlands, Postbus 396, 2130 AJ, Hoofddorp

Contact Person: Drs. Chris de Jong

Tel: +31 23 567 9600

Email: servicenl@spmsd.com

Website: www.spmsd.com



Sanofi Pasteur MSD is a joint venture between Sanofi Pasteur, the vaccine division of Sanofi, and Merck (known as MSD outside the US and Canada). Sanofi Pasteur MSD is headquartered in Lyon, France. At Sanofi Pasteur MSD, we believe that vaccination is a way to move Europe forward towards a future where people can stay ahead of disease. Vaccines are our passion because we know that they are the key to a world in better health.

Shoreland, Inc

P.O. Box 13795, Milwaukee, WI 53213-0795, USA

Contact Person: Bridget Mulgrew

Tel: +1 414-290-1900

Email: sales@shoreland.com

Website: www.shoreland.com



Shoreland Travax® is a web-based resource meeting the global health and safety information needs of travel medicine practitioners and medical managers. Shoreland editors and medical advisors turn up-to-date data into the information you require to make the care and counseling decisions you face with your patients and your personnel abroad.

Sigma-Tau S.p.A.

Head Office & Research Centre: Via Pontina Km. 30,400,

- 00040 Pomezia (Rome), Italy.

Contact Person: Antoinette Celli

Tel: +39 (0) 6 9139 3704 - 3432

Email: antoinette.celli@sigma-tau.it

Website: www.sigma-tau.it



Sigma-Tau is a leading, all Italian capital, International pharmaceutical Group.

Sigma-Tau R&D is focused on the following therapeutic areas: Rare and Neglected Diseases, Oncology, Immuno-oncology. Recently Sigma-Tau, in partnership with the non-profit organization Medicines for Malaria Venture (MMV) has developed an antimalarial product available in Europe, Cambodia and Ghana.



Sitata Inc.

36 Cumberland Dr. 2nd Floor, Mississauga, On, L5G 3M8, Canada

Contact Person: Adam St. John

Tel: +1 (888) 997-5279

email: astjohn@sitata.com or support@sitata.com

website: www.sitata.com



Advance your travel medicine practice with a hassle-free, web-based app to save you time and protect your clients. With Sitata, you can customize & store your medical recommendations online for each traveller's personal itinerary, and health & safety alerts are delivered to travellers in real-time to keep them informed while abroad.

South African Society of Travel Medicine (SASTM)

27 Linksfield Road Dunvegan,
Edenvale 1609 Gauteng South Africa

Contact: Mrs Marion Blewett

Tel: +27 11 025 3297

Email: admin@sastm.org.za

Website: www.sastm.org.za



The SASTM's Mission is to guide the profession in all aspects relating to the practice of travel medicine, liaise with the travel industry, consult with relevant authorities, advise the public and collaborate nationally and internationally on all aspects relating to Travel Medicine.

tropimed®

Rue Pedro Meylan 7 - P.O. Box 142 CH-1211 Geneva 17,
Switzerland

Contact Person: Inauen Manuela

Tel: +41 22 718 96 40

Email: custserv@tropimed.com

Website: www.tropimed.com



travel medicine expert program, updated daily since 1992

tropimed® is for health professionals and those providing travel medical advice. Provides specific information on 231 destinations, epidemiological maps and much additional information as needed.

tropimed® is available via the Internet, in standalone versions for Windows® or Mac® computers or network servers.

ISTM Expert Opinions in Travel Medicine

The Professional and Education Committee (PEC) of ISTM has developed an initiative entitled “Expert Opinion” as an educational vignette. New scenarios and opinions are presented regularly on the ISTM website at www.ISTM.org.

Expert Opinion presents a pre- or post-travel quandary that is answered by an invited ISTM member with expertise in the topic discussed. The international membership includes varied clinical approaches, and the expert is offering only an opinion on a particular subject and should not be taken as a directive for all patients or cases. The PEC encourages ISTM members to discuss additional aspects relating to the scenario on the TravelMed Listserv. The cases and Expert Opinions are retained on the site so that visitors have the ability to review previous scenarios.

- 2013** • **Case 1** (Poh Lian Lim, Singapore) — Advice on Dengue fever for an American student going to live two years in Asia
- 2012** • **Case 1** (Martin Haditsch, Leonding, Austria and Hannover, Germany) — TBE Advice for Honeymooners travelling to southern Austria, Switzerland and Germany
• **Case 2** (Christopher van Tilburg, United States of America) — Advice to adolescent traveler for sports competition at high altitude
- 2011** • **Case 1** (Pierre van Damme, Belgium) — Hepatitis A and B advice for a student travelling to India
• **Case 2** (Dale Carroll, USA) — YF vaccination for a pregnant woman traveling to Ivory Coast
• **Case 3** (Stephen Toovey, South Africa) — Malaria risk of a Swiss Traveler to Hong Kong, Thailand and India
- 2010** • **Case 1** (Hilary Simons, United Kingdom) — Spacing of live vaccines in a traveller to Ghana
• **Case 2** (David Freedman, United States of America) — Travel advice for a trip to Southern Africa
- 2009** • **Case 1** (Frank Bia, United States of America) — Follow-up positive TB skin tests
• **Case 2** (Joel E. Gallant, United States of America) — Occupational exposure to HIV
- 2008** • **Case 1** (Philippe Gautret, France) — Rabies post-exposure case from China
• **Case 2** (Buddha Basnyat, Nepal) — Enteric fever in a Danish expatriate to Nepal
• **Case 3** (Karin Leder, Australia) — Influenza in travellers

Please note the expert is offering only an opinion on a particular subject and should not be taken as a directive for all patients or cases. To access the information, please go to the ISTM Website at www.ISTM.org and select the link to Expert Opinions under Member News and Resources right on the home page.

We hope you find this ISTM Professional Education Committee initiative helpful in your practice. The cases are all available directly from the ISTM website at www.ISTM.org.



www.ISTM.org

International Society of Travel Medicine

Promoting healthy travel worldwide

Established 1991



ISTM Travel Medicine Teaching Slides

Enhance Your Travel Medicine Lectures!

This 158-slide PowerPoint slide set has been recently updated and has doubled in size since the 2008 version to include enhanced materials on special needs travelers (children, pregnant women and compromised hosts), and entirely new material on common post-travel syndromes and specific infections. The presentation is suitable for lecturing to both healthcare professionals and lay groups. Slides are grouped by subject area (e.g., Risk Assessment, Vaccines, Malaria, Travelers' Diarrhea, Special Needs Travelers, Post-Travel Syndromes) for easy customization of lectures. Material and teaching points are international in scope, allowing the presenter to elaborate on specific local dosing and availability issues.

Authors of the slideset are Eric Caumes, MD, Professor of Infectious and Tropical Diseases at the Hôpital Pitié-Salpêtrière in Paris, France and Bradley A. Connor, MD, Director of the New York Center for Travel and Tropical Medicine and Clinical Associate Professor of Medicine at Weill Medical College of Cornell University, New York, United States.

The slide set was peer-reviewed by key opinion leaders from Australia, France, Germany, Israel, Switzerland, South Africa, the United Kingdom and the United States of America, ensuring the international relevance and applicability of the content.



ISTM Distance Learning Program

Instant Access to a World of Information!

In an effort to expand the reach of its educational offerings, ISTM established a Distance Learning Program. With more than 60 sessions currently available, a range of relevant topics are accessible to all travel medicine practitioners, with both introductory and more advanced content.

Modules offer both video with synchronized slides, and audio with synchronized slides. Individual sessions range from 30 minutes to four hours. These modules can be ordered individually or with volume discounts, and are available for viewing over the internet for six months after purchasing.

The following are a few of the many titles or subject areas currently available:

- Dengue: Into the Future
- Emergencies in Travel Medicine
 - Travelers' Diarrhea
 - Preparation of Last Minute Travelers
- How to Start a Travel Clinic
- Malaria Prevention
- Rabies
- Preparing Your Patients for Mass Gatherings
- High Risk and Special Needs Travelers
- Special Populations: Business, Long-stay, and Visiting Friends or Relatives Travelers

Devoted to Learning. Devoted to Teaching.

www.ISTM.org



GlaxoSmithKline
Vaccines

GSK invites you to a Satellite symposium
on **Monday 20th May** (13.00 – 14.30) entitled
*Meningococcal Vaccination amongst the travel
population*

GSK is committed to the prevention of
life-threatening diseases and to the improvement
of public health across the globe.



Registered as GlaxoSmithKline Biologicals SA

Rue de L'Institut, 89 BE-1330 Rixensart. RPM Nivelles BE 0440.872.918

www.gsk.com